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1. Introduction 
This report describes the results from the 
fourteenth proficiency test conducted by the 
National Food Institute as the EU Reference 
Laboratory for Antimicrobial Resistance (EURL-
AR). This proficiency test focuses on 
antimicrobial susceptibility testing (AST) of 
enterococci, staphylococci and Escherichia coli. 
It is the seventh External Quality System 
Assurance System (EQAS) conducted for these 
microorganisms. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or elaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU-
FOOD). These results were then verified by the 
United States Food and Drug Administration 
(FDA), Centre for Veterinary Medicine. Finally, a 
fourth MIC determination was performed at 
DTU-FOOD after preparation of the agar stab 
culture for shipment to participants to confirm 
that the vials contained the correct strains with 
the expected MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by MS to 
report AST data to the European Food Safety 
Authority (EFSA), and complies with “the main 
objective of this EQAS to assess and improve 
the comparability of surveillance and 
antimicrobial susceptibility data reported to 
EFSA by the different NRLs”, as stated in the 
protocol. 
3) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance to 5%. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant. Since methods 
used for MIC determination have limitations, it 
is not considered a mistake to obtain a one-fold 
dilution difference in the MIC of a specific 
antimicrobial when testing the same strains. 
However, if the expected MIC is close to the 
breakpoint value for categorizing the strain as 
susceptible or resistant, a one-fold dilution 
difference, which is acceptable, may result in 
two different interpretations, i.e. the same strain 
will be categorized as susceptible and resistant, 
which will be evaluated as correct in one case 
and incorrect in the other if the evaluation is 
based on interpretation of MIC values. Since 
this report evaluates the interpretations of AST 
values, some participants may find their results 
classified as wrong even though the actual MIC 
they reported is only one-fold dilution different 
from the expected MIC. In these cases, the 
participants should be confident about the good 
quality of their performance of AST. In the 
organization of the EQAS we try to avoid these 
situations by choosing test strains with MIC 
values distant from the breakpoints for 
resistance, which is not always feasible for all 
strains and all antimicrobials. Therefore, the 
EURL-AR network unanimously established in 
2008 that if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be subtracted from the 
evaluation report.  
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This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRLs who 
meet once a year at the EURL-AR workshop. 
All conclusions presented in this report are 
publically available. However, participating 
laboratories are identified by codes and each 
code is known only by the corresponding 
laboratory. The full list of laboratory codes is 
confidential information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
 
2. Materials and Methods  
2.1 Participants in EQAS 2013 
A pre-notification to announce the EQAS 2013 
on AST of enterococci, staphylococci and E. 
coli was sent by e-mail on the 16th April 2013 to 
the 41 NRLs in the network (App. 1) including 
seven additional laboratories (one from each of 
the following countries: Iceland, Norway, 
Serbia, Spain, Switzerland, The Netherlands 
and Turkey). These were invited to take part in 
the EQAS 2013 on the basis of their 
participation in previous EQAS iterations and/or 
affiliation to the EU network. Participants 
represented all EU countries (except for 
Luxembourg) and Norway, Switzerland and 
Iceland (App. 2).  
In total, this report includes AST results of 
enterococci strains submitted by 29 
laboratories, and AST results of staphylococci 
 
Figure 1  Participating countries in susceptibility testing of Enterococci, staphylococci and/or E. coli  
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strains submitted by 34 laboratories and E. coli 
strains submitted by 34 laboratories (Figure 1). 
2.2 Strains  
Bacterial strains included in this EQAS (eight 
enterococci, eight staphylococci and eight E. 
coli) were selected among the DTU-Food strain 
collection on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per each 
bacterial species tested has been included in all 
EQAS iterations performed to date, which 
represents an internal control. 
AST of the EQAS strains was performed at 
DTU-Food by MIC determination using the 
Sensititre panels from Trek Diagnostic Systems. 
The MIC values obtained (App. 3) were used as 
reference values for this EQAS trial after 
verification performed by the U.S. FDA. Results 
from the following antimicrobials were however 
not verified by FDA: daptomycin, tigecycline, 
teicoplanin and ampicillin for enterococci.  
Ceftazidime,meropenem, colistin cefotaxime, 
cefotaxime+clavulanic acid, ceftazidime, 
ceftazidime+clavulanic acid, imipenem, 
imipenem+EDTA, florfenicol and trimethoprim 
for E. coli and furthermore, florfenicol, 
sulfamethoxazol and trimethroprim for 
Staphylococci. After comparison and 
verification of the MIC values obtained at DTU-
Food and FDA, the strains were inoculated in 
agar as stab cultures and dispatched to the 
participating laboratories. 
Reference strains E. faecalis ATCC 29212, S. 
aureus ATCC 25923, S. aureus ATCC 29213 
and E. coli ATCC 25922 were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
 
2.3 Antimicrobials  
The panels of antimicrobials recommended for 
AST in this trial are listed in Table 1. 
The antimicrobials tested were changed in 
relation to previous trials by adjusting to the 
new EFSA recommendations; however, since 
the work at EU level on the panel of 
antimicrobials which would become part of the 
EU regulation was ongoing at the time, the 
choice of the antimicrobial panel did not 
correspond to the final panel set in the new 
legislation. The antimicrobials included in the 
EQAS will again be revised for the next trial, to 
adjust to the final panel to be used in the EU 
monitoring starting in 2014. 
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document – M7-A9 
(2012) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Ninth Edition”. 
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as recommended by EFSA 
and described in the protocol (App. 4). Results 
of ESBL detection tests were interpreted 
according to the recommendations reported in 
the EUCAST expert rules.  
 
2.4 Distribution  
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time. In June 2013, bacterial strains in 
agar stab cultures were dispatched in double 
pack containers (class UN 6.2) to the 
participating laboratories according to the 
International Air Transport Association (IATA) 
regulations as UN3373, biological substances 
category B. 
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2.5 Procedure 
Participants were instructed to keep the agar 
stab cultures refrigerated until performance of 
AST according to the information posted on the 
EURL-AR website (App. 4b, 4c, 4d and 4e). In 
addition, instructions for interpretation of AST 
results were provided. For interpretation of MIC 
determination results, cut-off values were 
reported in the protocol (App. 4b: Tables 1, 2 
and 3). For interpretation of disk-diffusion (DD) 
method results, participants were advised to 
use interpretive breakpoints as in their routine 
methods. In both cases, the EQAS test strains 
should have been categorized as resistant or 
susceptible, and the EURL-AR recommended 
interpreting intermediate results as susceptible. 
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
to wild-type and non-wild-type strains. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. Alternatively, it was offered the 
possibility to fill-in a record sheet (provided with 
the protocol) and to send it to the EURL-AR by 
fax, mail or email. 
The record sheet contained also space for 
reporting the results (zone diameters in 
millimeters or MIC values in μg/ml) obtained for 
the reference strains. These results were 
compared to the quality control ranges reported 
by CLSI in documents M31-A3 (2008) / M100-
S23 (2013) (App. 5).  
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2013 
component 
Enterococci  Staphylococci  Escherichia coli  
Ampicillin , AMP Cefoxitin, FOX Ampicillin, AMP 
Chloramphenicol, CHL Chloramphenicol, CHL Cefotaxime, CTX 
Ciprofloxacin , CIP Ciprofloxacin, CIP Ceftazidime, CAZ 
Daptomycin, DAP Clindamycin, CLN Chloramphenicol, CHL 
Erythromycin, ERY Erythromycin, ERY Ciprofloxacin, CIP 
Gentamicin, GEN Florfenicol, FFN Colistin, COL 
Linezolid, LZD Gentamicin, GEN Florfenicol, FFN 
Quin.-Dalf. (Synercid), SYN Linezolid, LZD Gentamicin, GEN 
Teicoplanin, TEI Mupirocin, MUP Meropenem, MER 
Tetracycline, TET Penicillin, PEN Nalidixic acid, NAL 
Tigecycline, TGC Quin.-Dalf. (Synercid), SYN Sulfamethoxazole, SMX 
Vancomycin, VAN Sulfamethoxazole, SMX Tetracycline, TET 
 Tetracycline, TET Trimethoprim, TMP 
 Trimethoprim, TMP  
 Vancomycin, VAN  
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The database was finally closed and 
evaluations were made available to participants 
on the 10th September 2013. 
After this date, the participants were invited to 
login again to retrieve a database-generated 
individual report which contained an evaluation 
of the submitted results including possible 
deviations from the expected interpretations. 
Finally, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials 
3. Results 
The participants were asked to report results, 
including MIC values or inhibition zone 
diameters obtained by DD together with the 
categorisation as resistant or susceptible. Only 
the categorisation was evaluated, whereas the 
MIC values and disk diffusion inhibition zones 
were used as supplementary information. 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly subtracted from the 
general analysis if there are less than 75% 
correct results for a strain/antimicrobial 
combination in the ring trial. In this respect, we 
have noticed in the raw data analysis at 
database closing that four antimicrobial / strain 
combinations were causing 25% or more 
deviations and these were excluded from the 
analysis before the evaluation was opened to 
the participants. This was the case for ENT 
7.2/ampicillin (61%), ENT 7.2/Quinupristin-
dalfopristin (75%), ENT 7.3/ampicillin (71%) 
and ENT 7.3/quinupristin-dalfopristin (71%). 
Similarly, the results for Staphylococci for two 
combinations were excluded from the raw data 
analysis due to problems observed in relation to 
breakpoints. This was the case of strain ST 
7.4/ciprofloxacin (50%) and strain ST 7.6/ 
quinupristin+ dalfopristin (43%) which had low 
percentages of correct results as described 
above and were therefore excluded from the 
evaluation before the database evaluation was 
opened. The cause for these deviations was 
that the expected values were lying just one 
step from the breakpoint. For this reason, these 
tests were not considered representative of the 
capacity of the laboratories for performing AST 
and were therefore not interpreted in the 
database when the evaluation was performed. 
Similarly, the results for the combination EURL 
ENT 7.8/daptomycin were found to lead to a 
deviation level above 25% also because the 
expected value lay/was close to the breakpoint. 
Therefore, as the results were evaluated for the 
report, further analysis was carried out to 
decide if they should be omitted as well. 
In the EQAS 2013, the overall percentages of 
deviations from the expected results were 
1.5%, 2.2% and 0.9% for enterococci, 
staphylococci and E. coli, respectively (Figure 
2). These percentages were lower for 
enterococci, and E. coli trials when compared to 
the ones observed in 2012. The internal control 
strains (ENT-7.7, ST-7.4 and EC-7.4) followed 
the same decreasing pattern for the enterococci 
strain with 2.7 % deviation, while for E. coli the 
deviations were 0.5% as in 2012 and for 
staphylococci the deviation percent increased 
to 2.9% (Figure 2). Of note, these percentages 
do not include specific combinations 
strain/antimicrobial for which we observed less 
than 75% reported results in agreement with 
the expected results (detailed explanation is 
provided in the paragraphs below).  
3.1 Methods 
In the data analysis, results were grouped 
according to the methods used by the 
participants as follows. The agar dilution 
method and MIC determination were evaluated 
together as they are both quantitative methods 
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giving results corresponding to the MIC of the 
bacterial strain tested. The Rosco and DD 
methods were evaluated together since they 
are based on the same principle of antimicrobial 
diffusion in the agar. 
In the EQAS 2013, 26, 27 and 31 participants 
performed AST by MIC determination for 
enterococci, staphylococci and E. coli, 
respectively, and three, seven and three 
participants performed AST by agar diffusion 
techniques for enterococci, staphylococci and 
E. coli, respectively. 
3.2 Deviations overall 
The list of deviations is illustrated in Appendixes 
8a, 8b and 8c. Figure 2 shows the overall 
deviation levels. 
The percentages of deviations were less 
Table 2. Total number of antimicrobial susceptibility tests (AST) performed for each EQAS 2013 strain and percentage 
(%) of correct results 
Strain* No. AST 
No 
correct 
% 
correct Strain* 
No. 
AST 
No 
correct 
% 
correct Strain* 
No. 
AST 
No 
correct 
% 
correct 
ENT-7.1 231 229 99,1% ST-7.1 409 398 97,3% EC 7.1 404 402 99,5% 
ENT-7.2 220 215 97,7% ST-7.2 408 392 96,1% EC 7.2 406 401 98,8% 
ENT-7.3 220 218 99,1% ST-7.3 408 403 98,8% EC 7.3 407 405 99,5% 
ENT-7.4 261 258 98,9% ST-7.4 376 365 97,1% EC 7.4 406 404 99,5% 
ENT-7.5 236 232 98,3% ST-7.5 410 402 98,0% EC 7.5 405 400 98,8% 
ENT-7.6 234 232 99,1% ST-7.6 386 379 98,2% EC 7.6 404 398 98,5% 
ENT-7.7 261 254 97,3% ST-7.7 408 401 98,3% EC 7.7 404 402 99,5% 
ENT-7.8 255 255 100% ST-7.8 407 402 98,8% EC 7.8 407 402 98,8% 
*ENT, enterococci; ST, staphylococci; EC, Escherichia coli.  
         
0
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Figure 2 Overview of the percentages of deviations from expected results obtained in different EQAS iterations for the 
three bacterial species tested. The internal control strain is represented by a red line. 
 
Figure 3 EQAS 2013: Percentage of deviations from the expected interpretation subdivided by tested species and 
antimicrobial susceptibility test method used. 
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affected by the method used, than in previous 
years. Only for E. coli the results show a higher 
percentage of deviations performing AST by DD 
as compared to MIC determinations. For the 
enterococci the deviation percent obtained with 
DD was actually lower and for staphylococci it 
was similar (Figure 3), 
Overall, the percentage of results in agreement 
with the expected values ranged from a 
minimum of 96.1% (strain ST 7.2) to a 
maximum of 99.5% (strains EC 7.1, EC 7.3 and 
EC 7.7), as shown in Table 2. The E. coli trial 
resulted in the highest percentages of results in 
agreement with the expected values. 
Detailed analyses of the results obtained for 
each species are reported in the following 
paragraphs. 
3.2.1 Enterococci  
Analysis of results from the Enterococci trial 
showed that one additional antimicrobial 
combination had more than 25% deviation due 
to expected results being very close to the 
breakpoint. This was the case of the 
combination daptomycin and strain EURL ENT 
7.8 for which only 11 laboratories uploaded 
results and three of these reported results just 
one step above the expected result but already 
above the resistance breakpoint. These results 
were subtracted from the calculations in this 
report as they do not reflect the capacity of the 
laboratories to perform AST. 
In general, 99% of the results were interpreted 
correctly. Figure 3 shows the total percentage 
of deviations assigned to AST by MIC testing or 
DD. The percentage of deviation for the labs 
performing DD was lower in general (the DD 
column represents only three laboratories).  
Results deviating from expected interpretation 
subdivided by strain showed that percentage of 
deviations from expected results ranged from 
0.0% (ENT 7.8) to 2.7% (ENT 7.7) (Figure 4). 
Laboratories performing AST by DD reported 
very good results for most of the strains ranging 
from percentage of deviation of 0% (for ENT-
7.3, 7.4, 7.5, 7.6, 7.7 and 7.8) to 4% (for ENT-
7.2), as shown in Figure 4. Out of 29 
laboratories participating in the enterococci trial, 
only three performed AST by DD. Analysis of 
the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to gentamicin (3.9%) and 
ampicillin (3.5%) (Figure 5). An overview of 
obtained and expected results is reported in 
Appendix 7a. 
Enterococci identification (ID) 
For the first time in this EQAS, the participants 
were requested to identify the Enterococci 
species. The exercise went very well and only 
three deviations were obtained in 224 tests 
performed. One participant did not upload data 
for Enterococci ID (Lab #40). The registered 
deviations were obtained by three participants 
who failed to ID one strain each (Labs #11, #26 
and 45)  
11 
                                                             
 
3.2.2 Staphylococci  
Analysis of results from the Staphylococci trial 
showed that 97.8% of the results were 
interpreted correctly. Figure 3 shows the total 
percentage of deviations assigned to AST by 
MIC testing or DD. This shows that the 
percentage of deviation of the labs performing 
DD was similar between methods in general 
(the DD column represents seven laboratories).  
Analysis of results deviating from expected 
interpretation subdivided by strain showed that 
percentage of deviations from expected results 
ranged from 1.2% to 2.9% (Figure 6). The 
highest percentage (2.9%) of disagreement with 
the expected results was obtained for ST-7.4 
(Figure 6). The lowest percentage of 
disagreement with the expected results was 
1.2% for strain ST 7.3 and 7.8 (Figure 6). 
Laboratories performing AST by DD obtained 
results deviating from the expected categories 
in percentages comparable to the ones 
obtained by MIC determination, as shown in 
Figure 7. Out of 34 laboratories participating in 
the staphylococci trial, six performed AST by 
DD and one performed diffusion using Rosco 
tablets (for analysis purposes summed in the 
DD). 
Analysis of the results according to the tested 
 
Figure 4 Enterococci trial: results deviating from the expected interpretation subdivided by tested strain and 
antimicrobial susceptibility test method used  
 
 
Figure 5. Enterococci trial: results deviating from the expected interpretation according to tested 
antimicrobials. 
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antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to clindamycin and quinupristin-
dalfopristin (both 8.1% deviations), followed by 
sulfamethoxazole (4.9%) and trimethoprim 
(4.3%) (Figure 7). 
An overview of obtained and expected results is 
reported in Appendix 7b. 
 
Methicillin-resistant S. aureus 
Strains ST 7.1, 7.3, 7.4, 7.5, 7.7 and 7.8 were 
methicillin-resistant. Among 34 participants 
testing staphylococci strains, one (#45) did not 
report results concerning methicillin resistance. 
One participant (lab #39) failed in detecting 
methicillin resistance in strain ST 7.1 and two 
laboratories found either ST 7.2 (lab #6) or ST 
7.6 (lab #30) as false methicillin positive. 
All remaining results were correct. 
 
3.2.3 Escherichia coli  
Analysis of results from the E. coli trial showed 
that 99.1% of the results were interpreted 
correctly. Figure 3 shows the total percentage 
of deviations assigned to AST by MIC testing or 
DD.  The percentage of deviation of the labs 
 
Figure 6 Staphylococci trial: results deviating from the expected interpretation subdivided by tested strain 
and antimicrobial susceptibility test method used  
 
Figure 7. Staphylococci trial: results deviating from the expected interpretation according to tested 
antimicrobial. 
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performing DD was higher (4.6%) in relation to 
the MIC testing results that showed only 0.5% 
deviations (the DD column represents three 
laboratories). 
Analysis of results deviating from expected 
interpretation subdivided by strain showed that 
percentage of deviations from all expected 
results ranged from 0.5% to 1.5% (Figure 8). 
The highest percentage (1.5%) of disagreement 
with expected results was obtained for EC 7.6 
(Figure 8). Laboratories performing AST by DD 
obtained results deviating from the expected 
categories in percentages higher than the ones 
obtained by MIC determination, as shown in 
Figure 8. The results obtained by DD varied 
from 0.0%- 8.6% (Figure 8). Out of 34 
laboratories participating in the E. coli trial, 
three performed AST by DD. 
An overview of obtained and expected results is 
reported in Appendix 7c. 
Analysis of the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
 
 
 
Figure 8 E. coli  trial: results deviating from the expected interpretation subdivided by tested strain and 
antimicrobial susceptibility test method used  
 
Figure 9. E. coli trial: results deviating from the expected interpretation according to tested antimicrobials. 
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interpretations were obtained in testing 
susceptibility to ceftazidime and 
sulfamethoxazole (2.7%), (Figure 9). 
Ciprofloxacin caused the third highest deviation 
percentage (1.8%) while tests of susceptibility 
to the remaining antimicrobials resulted in less 
than 1.0% results deviating from the expected 
(Figure 9). No deviations were observed for 
cefotaxime, tetracycline and meropenem 
susceptibility testing (Figure 9). 
An overview of obtained and expected results is 
reported in Appendix 7c. 
 
Beta-lactamase-producing E. coli 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations the confirmatory 
test for ESBL production requires use of both 
cefotaxime (CTX) and ceftazidime (CAZ) alone 
and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as i) 
a ≥ 3 twofold concentration decrease in an MIC 
for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC 
when tested alone (E-test 3 dilution steps 
difference; MIC CTX : CTX/CL or CAZ : CAZ/CL 
ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone 
diameter for either antimicrobial agent tested in 
combination with clavulanic acid vs. its zone 
when tested alone (CLSI M100 Table 2A; 
Enterobacteriaceae). The presence of synergy 
indicates ESBL production. Resistance to 
cefepime gives further indication of ESBL 
production. 
Confirmatory test for carbapenemase 
production requires the testing of meropenem 
(MER).  
Detection of AmpC-type beta-lactamase 
producing bacteria can be performed by testing 
the isolates for susceptibility to cefoxitin (FOX). 
Resistance to FOX could indicate the presence 
of an AmpC-type beta-lactamase, that may be 
verified by PCR and sequencing. 
The classification of the phenotypic results 
should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating as: 
• Presumptive ESBL: strains with positive 
synergy test, susceptible to cefoxitin 
and resistant to cefepime 
• Presumptive ESBL+pAmpC: -strains 
with positive or negative synergy test, 
resistant to cefoxitin and resistant to 
cefepime 
• Presumptive pAmpC phenotype: -
strains with negative synergy test  
• Presumptive carbapenemase 
phenotype: -strain resistant to 
meropenem 
• Unusual phenotype: any other 
combinations 
In this EQAS all laboratories have uploaded 
results at least for the strains harbouring 
resistance to the cephalosporins tested. 
In this trial, EC 7.2 and EC 7.4 were extended-
spectrum beta-lactamase (ESBL) producers 
and EC 7.3 and EC 7.8 were AmpC-producers. 
For the strain 7.2 as the cefepime resistance 
was difficult to detect, the result “unusual 
phenotype” was accepted as correct as well as 
the classification as presumptive ESBL. 
Deviations from expected results were obtained 
as follows: 
Two participants (Lab #6 and #22) did not 
identify EC 7.4 as ESBL producing strain but 
they classified it as presumptive ESBL+pAmpC.  
This can be explained as Lab #6 has found this 
strain resistant to cefoxitin. For Lab #22 the 
reason might be related to the interpretation as 
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the results uploaded would indicate it as an 
ESBL phenotype. Regarding the AmpC strains, 
strain EC 7.3 was misclassified as 
ESBL+pAmpC by six laboratories which either 
considered it as ESBL+pAmpC (Lab #6, #22, 
#40, #45 and #58) or as an unusual phenotype 
(#37). Most of these labs seemed to have 
misclassified the phenotype, whereas lab #22 
found synergy to ceftazidime and Lab #58 
found resistance to cefepime in addition to the 
AmpC phenotype. Regarding strain EC 7.8, the 
results were misclassified by seven laboratories 
three of which considered it as an unusual 
phenotype (Lab #19, #37 and #45). These labs 
had different reasons for the misclassification. 
Lab#19 reported synergy for ceftazidime, 
whereas Lab #37 did not find the isolate 
resistant to cefoxitin and Lab #45 reported 
results consistent to an AmpC profile but 
considered the profile as unusual. Three 
participants considered strain EC 7.8 as 
harboring both ESBL and pAmpC (Labs #6, #39 
and #58). However, two of them reported 
results that represented an AmpC phenotype 
whereas Lab#58 reported this strain to be 
additionally resistant to cefepime. One 
participant considered strain EC 7.8 as an 
ESBL based on the determination of synergy for 
cefotaxime with clavulanic acid, however this 
laboratory did not provide results for cefoxitin or 
cefepime (Lab #41) (please refer to protocol, 
App.4b). 
 
3.3 Deviations by participating 
laboratory 
Figures 10, 11 and 12 illustrate the percentage 
of deviations for each participant laboratory. 
Two out of 29 participants obtained a 
percentage of deviations from expected results 
higher than 5% for enterococci (Figure 10), 
three out of 34 participants had above 5% 
deviation in the staphylococci trial (Figure 11) 
and three out of 34 participants had above 5% 
deviation in the E. coli trial. These results will be 
in focus in the next sections. 
 
3.3.1 Enterococci  
Participant #11 obtained the largest number of 
deviations (7.4%). This percentage of 
deviations was due to four deviations for strain 
ENT 7.5. After communicating with this 
laboratory it was found that the participant had 
mixed up this strain with the Enterococcus 
faecium control strain BM 4147 why the four 
deviations could be explained. Re-testing the 
actual ENT 7.5 strain allowed to obtained the 
expected results. 
The second highest level of deviations was 
7.1% obtained by Lab #26. All the deviations 
were caused by MICs for gentamicin much 
higher than those expected, leading to 
misinterpretation of susceptible strains as 
resistant. 
For further information please consult the 
overview in the Appendixes (App. 8a). 
 
In summary, 27 of the 29 participants in the 
enterococci trial achieved the acceptance level 
by having less than 5% of results deviating from 
the expected values (Figure 10). Among the two 
participants who did not meet the acceptance 
level, none was considered an outlier (Figure 
10). 
 
3.3.2 Staphylococci  
Analysis of laboratory performance of AST 
showed that three out of 34 participants 
obtained a percentage of deviations from 
expected results higher than 5.0% (Figure 11). 
One out of seven participants performing AST 
by DD obtained more than 5.0% deviations 
from expected results (Figure 11). 
Participant #39 and #6 were considered outliers 
due to the percentages of deviations obtained. 
The participant with highest level of deviation 
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(Lab #39) had 14.3% deviations corresponding 
to nine deviations These deviations were 
regarding the testing of strains towards 
ciprofloxacin, clindamycin and erythromycin (all 
of them are deviations towards reporting higher 
MIC results than expected). After conversations 
with this laboratory the results for six of these 
deviations might have to do with wrong reading 
of the MIC for clindamycin, regarding 
ciprofloxacin and erythromycin further 
investigations are needed. 
Participant #6 obtained 10.9% due to 12 
deviations from expected results. These 
deviations are regarding the testing of strains 
towards several antimicrobials (many of them 
are deviations where higher MIC results than 
expected were obtained and two maybe related 
to the interpretation or breakpoint. The 
participant suspected that the problem has 
been the calibration of the autoinoculator and 
new calibration has been solicited and it was 
reported to the EURL-AR that the results were 
improved.  
In summary, 31 of 34 participants in the 
staphylococci trial achieved the acceptance 
level by having less than 5.0% of results 
deviating from the expected values (Figure 11).  
Deviations from expected results obtained by 
each participant in the staphylococci trial are 
reported in Appendix 8b. 
 
3.3.3 Escherichia coli  
Analysis of laboratory performance of AST 
showed that two out of 34 participants obtained 
a percentage of deviations from expected 
results higher than 5% (Figure 12).  
Participant # 45 obtained eight deviations from 
 
 
 
*Laboratories performing AST by disk diffusion 
Figure 10. Percentage of deviations from expected results obtained by each laboratory in the 
enterococci trial. The laboratories were ranked by decreasing percentage of deviations from expected 
results in antimicrobial susceptibility testing. 
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expected results accounting for a total deviation 
of 8.3%. These deviations are regarding the 
testing of strains towards several antimicrobials 
with disk diffusion and they may be related to 
the interpretation or breakpoint or test results 
whereas participant #46 had 5.2% deviations by 
testing ampicillin and ciprofloxacin by agar 
dilution and sulfamethoxazole and trimethoprim 
by E-test. (App. 8c).In summary, 32 of 34 
participants in the E. coli trial achieved the 
acceptance level by having less than 5% of 
results deviating from the expected values.  
 
*Laboratories performing AST by disk diffusion 
Figure 11 Percentage of deviations from expected results obtained by each laboratory in the 
Staphylococci trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing 
 
*Laboratories performing AST by disk diffusion 
Figure 12. Percentage of deviations from expected results obtained by each laboratory in the 
Escherichia coli trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing 
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3.4 Deviations from expected 
results for the reference strains 
The results for antimicrobial susceptibility 
testing of the reference strains have been 
evaluated according to the CLSI-established 
quality control (QC) ranges (App. 5). 
3.4.1 Enterococcus faecalis ATCC 29212 
26 participants performed AST of E. faecalis 
ATCC 29212 by MIC determination. Seven 
results were found outside of range. In 
summary, out of 228 tests performed 221 were 
correct (Table 3). 
As CLSI has not published a QC range for E. 
faecalis ATCC 29212 using DD, the two 
laboratories (#40 and #45) that have entered 
data for the reference strain performing this 
method for AST could not be evaluated. One 
participant performing AST of enterococci by 
DD (#15) did not provide data for the 
Enterococci reference strain. 
3.4.2a Staphylococcus aureus ATCC 25923 
Six participants performed AST of S. aureus 
ATCC 25923 by DD. One result outside of the 
QC range was obtained for cefoxitin, penicillin, 
sulfisoxazole, vancomycin and tetracycline 
susceptibility tests. In summary, out of 49 tests 
performed by DD overall, 44 were correct. One 
participant (lab # 4) performed AST of S. aureus 
ATCC 25923 by Rosco method. This participant 
(lab #4) obtained one results outside the QC 
range for cefoxitin. 
3.4.2b Staphylococcus aureus ATCC 29213 
Twenty-six participants performed AST of S. 
aureus ATCC 29213 by MIC determination 
(Table 5) and one additional laboratory #46 did 
perform MIC testing but did not upload data for 
this reference strain. In this EQAS, two 
deviations were obtained, one for clindamycin 
and one for penicillin. In summary, out of 283 
tests performed, 281 were correct. 
 
 
 
 
 
 
Table 3. Antimicrobial susceptibility testing of 
Enterococcus faecalis ATCC 29212 by MIC 
determination: deviations from expected values. 
Antimicrobial 
Proportion 
outside of 
range 
Below QC 
range 
Above QC 
range 
Ampicillin  1/21 (5%) - >2 steps 
Chloramphenicol 0/26 (0%) - - 
Ciprofloxacin  1/19 (5%) - 2 steps 
Daptomycin 0/9 (0%) - - 
Erythromycin 0/26 (0%) - - 
Gentamicin 0/24 (0%) - - 
Linezolid 1/23 (4%) 1 step - 
Quinu-dalfo-pristin  1/16 (6%) - 1 step 
Teicoplanin 1/3 (33%) >5 steps - 
Tetracycline 0/26 (0%) - - 
Tigecycline 1/10 (10%) - 1 step 
Vancomycin 1/25 (4%) - 3 steps 
 
Table 4. Antimicrobial susceptibility testing of 
Staphylococcus aureus ATCC 29213 by MIC 
determination: deviations from expected values. 
Antimicrobial 
Proportion 
outside of 
range 
Below 
QC 
range 
Above QC 
range 
Cefoxitin 0/21 (0%) - - 
Chloramphenicol 0/25 (0%) - - 
Ciprofloxacin 0/25 (0%) - - 
Clindamycin 1/21 (5%) - 5 steps 
Erythromycin 0/26 (0%) - - 
Florfenicol 0/6 (0%) - - 
Gentamicin 0/25 (0%) - - 
Linezolid 0/15 (0%) - - 
Penicillin 1/26 (4%) 1 step - 
Quinu-dalfo-pristin 0/15 (0%) - - 
Sulfisoxazole 0/12 (0%) - - 
Tetracycline 0/26 (0%) - - 
Trimethoprim 0/25 (0%) - - 
Vancomycin 0/15 (0%) - - 
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3.4.3 Escherichia coli ATCC 25922 
Three participants performed AST of E. coli 
ATCC 25922 by DD. Only one deviation was 
observed by DD for ampicillin. In summary, out 
of 29 tests performed overall, 28 were correct. 
Thirty participants performed AST of E. coli 
ATCC 25922 by MIC determination and one 
participant (Lab #46) performed MIC 
determination but did not upload reference 
strain data even though this is a compulsory 
part of the EQAS. Four deviations were 
observed which were all for ciprofloxacin (Table 
5). In summary, out of 344 tests performed, 340 
were correct. For further information please 
consult App 6a, 6b and 6c. 
 
 
4. Discussion 
4.1 General overview 
In the overall analysis of the results, it was 
observed that the levels of deviations from the 
expected results were comparable to last year 
for AST of staphylococci and E. coli, while there 
was a decrease in deviations from the expected 
results for AST of enterococci (Figure 2). The 
percentage of deviations from the expected 
results for AST of the internal control strains 
followed a trend towards a decrease for 
enterococci, maintained the same level for E. 
coli and increased for the staphylococci internal 
control strain (Figure 2).  
It is important to consider that the number of 
EQAS participants changes from year to year, 
which implies that comparisons among different 
EQAS iterations are difficult to interpret. 
Furthermore, results from three laboratories 
from EU–affiliated countries non-MS were 
included in this report.  
The EURL-AR has emphasized the need for 
harmonization of AST methodology among 
NRLs, and has recommended MIC 
determination on several occasions. In this 
EQAS trial, the number of participants 
performing MIC determination is comparable to 
the high numbers observed last year and the 
new EU regulation will be based on MIC testing 
alone. 
4.2 Enterococci  
The percentages of results deviating from the 
expected interpretations varied from 0.0% to 
2.7% among the different test strains (Figure 4). 
These percentages of deviation are quite lower 
than the 2012 trial and most of the deviations 
were due to deviations occurring in testing MIC 
even though strains ENT 7.1 and 7.2 showed 
some deviations testing by DD (Figure 4).  
Even though CLSI does not provide a QC range 
for the testing of the reference strain by DD, the 
results of DD were found quite good this time 
as DD was performed by laboratories 
experienced in this method. 
The number of participants submitting more 
than 5% results deviating from the expected 
interpretation was two and none were 
considered outliers (Figure 10), which is less 
Table 5. Antimicrobial susceptibility testing of 
Escherichia coli ATCC 25922 by MIC: deviations from 
expected values. 
Antimicrobial 
Proportion 
outside of 
range 
Below 
QC 
range 
Above QC 
range 
Ampicillin 0/30 (0%)   
Cefotaxime 0/30 (0%)   
Ceftazidime 0/28 (0%)   
Chloramphenicol 0/29   
Ciprofloxacin 4/30 (13%)  1 step 
Colistin 0/24 (0%)   
Florfenicol 0/24 (0%)   
Gentamicin 0/30 (0%)   
Meropenem 0/8 (0%)   
Nalidixic acid 0/30 (0%)   
Sulfisoxazole 0/21 (0%)   
Tetracycline 0/30 (0%)   
Trimethoprim 0/30(0%)   
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than last year. The participants have been 
contacted by the EURL-AR to identify possible 
causes of this unsatisfactory performance and 
to improve the quality of results. Furthermore 
the level of deviation was in general lower than 
in the 2012 iteration.  
The number of participants performing AST with 
100% agreement with the expected results was 
15 (52%), which is a higher level than last year.  
AST of the quality control strain E. faecalis 
ATCC 29212 was very good for the 26 
participants that tested this strain by MIC 
determination (Table 3). In summary, out of 228 
tests performed overall, 221 (97%) were within 
range.  
4.3 Staphylococci  
The percentages of results deviating from the 
expected interpretations ranged from 1.2% to 
3.9% among the different test strains (Figure 6). 
The percentages of deviations from expected 
results generated by participants performing 
MIC and DD were this time similar in general.  
However, some higher deviation levels were 
observed for DD when testing particular strains 
(Figure 6).  
Identification of methicillin-resistant strains was 
in generally satisfactory, which demonstrated 
that laboratories within the EURL-AR network 
correctly identify MRSA. However, a few issues 
are prevailing. One participant (Lab #45) did still 
not report results for methicillin resistance and 
one lab (Lab #39) failed in detecting methicillin 
resistance in strain ST 7.1 because they have 
not set up the recommended testing method. 
Furthermore, two laboratories found either ST 
7.2 (Lab #6) or ST 7.6 (Lab #30) as false 
methicillin positive. 
Three participants (Lab #9, #6 and #36) 
submitted results with more than 5% deviations 
from the expected interpretation (Figure 11), 
which is similar to last year. Two outliers were 
observed (Lab #39 and #6) with percentages of 
deviation up to 14.3% and 10.9%, respectively. 
The EURL-AR has contacted the three 
participants to identify possible causes of this 
unsatisfactory performance and to improve the 
quality of results. 
The number of participants performing AST with 
100% agreement with the expected results was 
lower than in the past year and consisted of 10 
participants (29%). 
AST of the quality control strain S. aureus 
ATCC 25923 (for DD) resulted in 90% correct 
tests (Table 4), and AST of the quality control 
strain S. aureus ATCC 29213 (for MIC 
determination) resulted in 99% correct tests 
(Table 5). Overall, this performance was quite 
satisfactory.  
4.4 Escherichia coli  
The percentages of results deviating from the 
expected interpretations varied from 0.5% to 
1.5% among the different test strains (Figure 8). 
These percentages of deviations from expected 
results were lower than in the previous year and 
mainly generated by participants performing 
AST by DD (Figure 8).  
Susceptibility tests to ceftazidime and 
sulfamethoxazole resulted in the highest 
percentages (2.7%) of results deviating from 
the expected interpretations (Figure 9). For 
ceftazidime, the incorrect classification was 
mostly represented by resistant strains reported 
as susceptible by testing using DD, one 
susceptible strain interpreted as resistant using 
DD and one deviation due to one step lower 
MIC testing that influenced the interpretation 
(App. 8c). For sulfamethoxazole all of the 
deviations were related to considering resistant 
strains expected to be susceptible, which might 
be related to the end-point reading of this drug 
(App. 8c).  
The number of participants submitting more 
than 5% results deviating from the expected 
interpretation was two, which is lower than last 
year when three participants performed outside 
the acceptance level (Figure 12). The 
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Laboratory obtaining highest deviation levels at 
8.3% (Lab #45) performed testing E. coli by DD 
whereas the second highest obtaining 5.2% 
deviations (Lab #46) did MIC testing (Figure 
15). The two laboratories reporting deviation 
levels above the threshold have been contacted 
by the EURL-AR to identify possible causes of 
this unsatisfactory performance and to improve 
the quality of results. 
The number of participants performing AST with 
100% agreement with the expected results was 
20 (59%). 
Detection of beta-lactamases of the ESBL and 
AmpC-type should be further improved 
especially concerning the classification of the 
profiles found, especially taking in account the 
possibility of mixed profiles as it is included in 
the EFSA classification included in the new EC 
regulation (EU Decision 2013/652/EC) 
Therefore we still consider there is some need 
for improvements for correct performance and 
interpretation of ESBL and AmpC confirmatory 
tests as well as detection of carbapenemases.  
AST of the quality control strain E. coli ATCC 
25922 resulted in 97% and 99% correct tests by 
DD and MIC determination, respectively (Table 
5). Overall, this performance was quite 
satisfactory. However, as for previous years the 
majority of deviations was observed for testing 
ciprofloxacin and this results must be improved 
in future trials since ciprofloxacin is among the 
critically important antimicrobials as defined by 
the WHO. The participant with highest 
deviations for testing E. coli with DD reported 
data for the reference strain with only one 
deviation for testing ampicillin, however, the 
testing for this antimicrobial drug is not found 
deviating for the test strains. The participant 
with the second highest deviation level (Lab # 
46) performed MIC determination but did not 
upload data for the testing of the reference 
strain. 
5. Conclusions 
The number of laboratories not performing AST 
within the acceptable level (i.e. > 5% results 
deviating from the expected values) was three 
for the Staphylococci trial and two for the E. coli 
and enterococci trials. In the enterococci and E. 
coli trial none of them was considered as 
outliers, whereas for the staphylococci trial, two 
laboratories were considered outliers due to 
their higher deviation levels. Since one of the 
tasks of the EURL-AR is to give specific 
recommendations targeting individual difficulties 
in performing acceptable AST, laboratories 
outside the acceptable level have been 
contacted to assess individually the causes of 
inadequate AST performance and provide 
guideline to improve the methods used. These 
individual contacts should be taken as an 
opportunity to improve knowledge on AST.  
One participant did not provide data on 
methicillin resistance and false negative and 
false positive results were reported in this trial, 
therefore the EURL-AR will also follow up on 
any needs regarding the implementation of the 
correct detection and confirmation methods. 
Additional improvements are needed to 
correctly identify E. coli producing beta-
lactamases of the ESBL and AmpC-type as this 
is a priority area within the EURL-AR activities. 
We strongly encourage participants having 
problems in identifying these strains to perform 
a re-test of the test strains as a training 
exercise and to contact the EURL-AR in case 
any discussion is needed. 
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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Appendix 1. Pre notification EURL-AR EQAS 2013 
EQAS 2013 FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING OF E. COLI, 
STAPHYLOCOCCI AND ENTEROCOCCI, AND IDENTIFICATION AND TYPING OF MRSA 
 The EURL-AR announces the launch of another EQAS, thus providing the opportunity for proficiency 
testing which is considered an essential tool for the generation of reliable laboratory results of consistently 
good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci and 
eight enterococci isolates. The EQAS on identification and typing of MRSA strains will consist on the 
confirmation of identification and methicillin resistance by multiplex PCR for the eight Staphylococcus 
isolates and two isolates provided additionally for the MRSA trial. Additionally, spa typing of the strains 
confirmed as MRSA is offered as an optional module. 
Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 
4224), S. aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) 
(for MIC) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance and additional designated laboratories 
performing the selective isolation and identification of MRSA from pig farms. These laboratories do not 
need to sign up to participate but are automatically regarded as participants. You may contact the EQAS-
coordinator, if you wish to inform of changes. Participation is free of charge for all above-mentioned 
designated laboratories. 
 TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: eight E. coli, ten staphylococci, 
eight enterococci and for new participants also the QC strains mentioned above. Please provide the EQAS 
coordinator with documents or other information that can simplify customs procedures (e.g. specific text that 
should be written on the pro-forma invoice). To avoid delays, we kindly ask you to send this information 
already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2013. The protocol for this 
proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than the 6th of 
September 2013 via the password-protected website. Upon reaching the deadline, each participating 
laboratory is kindly asked to enter the password-protected website once again to download an automatically 
generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In the report, 
laboratories will be presented coded, which ensures full anonymity. The EURL-AR and the EU Commission, 
only, will have access to un-coded results. The report will be publicly available. 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter which will be carried out in October 2013 
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Lina Cavaco - EURL-AR 
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Appendix 2- List of participants 
Institute   Country E coli Ent Staph 
Austrian Agency for Health and Food Safety  Austria x x x 
Institute of Public Health Belgium x   x 
Veterinary and Agrochemical Research Centre Belgium     x 
Nacional Diagnostic and Research Veterinary Institute Bulgaria x x x 
Croatian Veterinary Institut Croatia x   x 
Veterinary Services  Cyprus x x x 
State Veterinary Institute Praha Czech Republic x x x 
SVI Olomouc Czech Republic     x 
National Food Institute Denmark x x x 
Estonian Veterinary and Food Laboratory Estonia x x x 
Finnish Food Safety Authority EVIRA Finland x x x 
Agence nationale de sécurité sanitaire ANSES- Maisons-Alfort France     x 
Agence nationale de sécurité sanitaire ANSES - Ploufragan France x   x 
Agence nationale de sécurité sanitaire ANSES - Lyon France x x x 
Agence nationale de sécurité sanitaire ANSES - Fougères  France x x   
Federal Institute for Risk Assessment  Germany x x x 
Veterinary Laboratory of Chalkis Greece x   x 
Central Agricultural Office Veterinary Diagnostic Directorate Hungary x   x 
University of Iceland Iceland x x x 
Central Veterinary Research Laboratory Ireland x x x 
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy x x x 
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia x x x 
National Food and Veterinary Risk Assessment Institute Lithuania x x x 
Public Health Laboratory Malta x x x 
Food and Consumer Product Safety Authority (VWA) Netherlands x x x 
Central Veterinary Institute of Wageningen UR Netherlands x x x 
Faculty of Veterinary Medicine, Netherlands     x 
Veterinærinstituttet Norway x x x 
National Veterinary Research Institute Poland x x x 
Laboratorio National de Investigacáo Veterinaria  Portugal x x x 
Institute for Hygiene and Veterinary Public Health Romania x x x 
Institute for Diagnosis and Animal Health Romania x x x 
State Veterinary and Food Institute  (SVFI) Slovakia  x x x 
National Veterinary Institute Slovenia x x x 
Laboratorio Central de Sanidad, Animal de Santa Fe  Spain     x 
Laboratorio Central de Sanidad, Animal de Algete  Spain x x   
VISAVET Health Surveillance Center, Complutense University Spain x x x 
Agencia Espanola de Seguridad Alimentria y Nutricion Spain       
National Veterinary Institute, SVA Sweden x x x 
Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland x x x 
Public Health England - Colindale UK x x x 
The Veterinary Laboratory Agency United Kingdom x x x 
 
NRL's   
non- NRL enrolled for  EQAS   
not EU-member state   
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Appendix 3a- Expected results for the enterococci trial (MIC- values and interpretations) 
Strain nr Species DAP TIG TEI Amp CHL CIP ERY GEN LZD Q-D TET VAN 
EURL ENT 7.1 E. faecalis 2 0,06 <=0,25 <=2 8 2 2 <=16 2 16 <=1 2 
EURL ENT 7.2 E. faecium 4 0,06 <=0,25 8 8 1 >32 <=16 2 4 <=1 <=1 
EURL ENT 7.3 E. faecium 1 0,06 >32 4 8 1 >32 <=16 2 8 >32 >32 
EURL ENT 7.4 E. faecium 4 0,03 0,5 <=2 8 8 2 <=16 2 1 <=1 2 
EURL ENT 7.5 E. faecalis 2 0,06 <=0,25 <=2 8 1 >32 >1024 2 16 >32 1 
EURL ENT 7.6 E. faecalis 1 0,12 <=0,25 <=2 >64 1 >32 512 2 16 >32 1 
EURL ENT 7.7 E. faecium 0,25 0,06 >32 4 8 <=0,5 1 <=16 2 4 >32 >32 
EURL ENT 7.8 E. faecium 4 0,03 <=0,25 >32 8 64 >32 >1024 2 2 <=1 2 
              Strain nr Species DAP TIG TEI Amp CHL CIP ERY GEN LZD Q-D TET VAN 
EURL ENT 7.1 E. faecalis S NA S S S S S S S NA S S 
EURL ENT 7.2 E. faecium S S S R S S R S S S S S 
EURL ENT 7.3 E. faecium S S R S S S R S S R R R 
EURL ENT 7.4 E. faecium S S S S S R S S S S S S 
EURL ENT 7.5 E. faecalis S NA S S S S R R S NA R S 
EURL ENT 7.6 E. faecalis S NA S S R S R R S NA R S 
EURL ENT 7.7 E. faecium S S R S S S S S S S R R 
EURL ENT 7.8 E. faecium S S S R S R R R S S S S 
 
  Resistant 
  Not applicable 
Abbreviations: DAP- daptomycin, TIG- tigecycline, TEI- teicoplanin, AMP-ampicillin, CHL-chloramphenicol, CIP- ciprofloxacin, ERY- erythromycin, GEN- 
gentamicin, LZD- linezolid, Q-D- quinupristin-dalfopristin, TET- tetracycline, VAN- vancomycin 
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Appendix 3b - Expected results for the staphylococci trial (MIC-values and interpretations) 
 
Strain nr Species VAN Q-D LZN MUP CLN CHL CIP ERY FFN FOX GEN PEN SMX TET TMP methicillin R 
EURL ST 7.1 S. aureus 1 0,5 4 0,06 0,12 8 0,25 0,5 4 8 <=0,25 0,5 <=32 <=0,5 1 yes 
EURL ST 7.2 S. aureus 2 1 2 0,06 0,12 8 0,5 0,5 4 4 <=0,25 8 <=32 <=0,5 2 no 
EURL ST 7.3 S. aureus 1 2 2 0,12 8 8 0,25 0,5 4 16 0,5 >16 <=32 >32 >32 yes 
EURL ST 7.4 S. aureus 0,5 0,5 2 0,06 0,12 8 2 <=0,25 4 8 >16 >16 256 32 <=0,5 yes 
EURL ST 7.5 S. aureus 1 0,5 2 0,06 0,12 8 0,25 0,5 4 16 0,25 8 <=32 >32 1 yes 
EURL ST 7.6 S. aureus 1 2 2 0,12 >256 16 0,5 >16 8 4 >16 16 <=32 >32 >32 no 
EURL ST 7.7 S. aureus 1 2 2 0,12 8 8 0,25 0,5 4 8 <=0,25 >16 <=32 >32 >32 yes 
EURL ST 7.8 S. aureus 1 1 1 0,12 0,12 8 0,25 <=0,25 2 8 <=0,25 8 <=32 >32 1 yes 
                  
Strain nr Species VAN Q-D LZN MUP CLN CHL CIP ERY FFN FOX GEN PEN SMX TET TMP methicillin R 
EURL ST 7.1 S. aureus S S S S S S S S S R S R S S S yes 
EURL ST 7.2 S. aureus S S S S S S S S S S S R S S S no 
EURL ST 7.3 S. aureus S R S S R S S S S R S R S R R yes 
EURL ST 7.4 S. aureus S S S S S S R S S R R R R R S yes 
EURL ST 7.5 S. aureus S S S S S S S S S R S R S R S yes 
EURL ST 7.6 S. aureus S R S S R S S R S S R R S R R no 
EURL ST 7.7 S. aureus S R S S R S S S S R S R S R R yes 
EURL ST 7.8 S. aureus S S S S S S S S S R S R S R S yes 
  
  Resistant 
Abbreviations: VAN- vancomycin, Q-D- quinupristin-dalfopristin, LZD- linezolid, MUP- mupirocin, CLN-Clindamycin, CHL-chloramphenicol, CIP- 
ciprofloxacin,ERY- erythromycin, FFN- florfenicol, FOX- cefoxitine, GEN- gentamicin, PEN- penicillin, SMX- sulphamethoxazol, TET- tetracycline, TMP- 
trimethroprim, methicillin R- methicllin resistance confirmed. 
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Appendix 3c- Expected results for the E. coli trial (MIC- values and interpretations)  
 
Strain nr Species MER COL AMP CAZ CHL CIP CTX FFN FOX GEN NAL SMX TET TMP Presumptive phenotype 
EURL EC 7.1 E. coli 0,03 <=1 >32 0,125 4 0,12 <=0,12 2 2 <=0,5 >64 >1024 >32 >32 Not resistant 
EURL EC 7.2 E. coli 0,03 <=1 >32 1 4 <=0,015 >4 4 4 0,5 4 >1024 >32 >32 ESBL /Unusual phenotype 
EURL EC 7.3 E. coli 0,03 <=1 >32 8 4 <=0,015 4 4 64 0,5 2 <=16 <=2 <=1 pAmpC 
EURL EC 7.4 E. coli 0,03 <=1 >32 2 4 <=0,015 >4 4 4 0,5 2 <=16 <=2 <=1 ESBL 
EURL EC 7.5 E. coli 0,03 <=1 4 0,25 8 0,03 0,125 8 4 1 4 <=16 <=2 <=1 Not resistant 
EURL EC 7.6 E. coli 0,03 <=1 >32 0,25 32 0,03 <=0,125 16 4 1 4 <=16 >32 <=1 Not resistant 
EURL EC 7.7 E. coli 0,03 <=1 >32 0,125 >64 <=0,015 <=0,125 >64 2 16 2 >1024 <=2 >32 Not resistant 
EURL EC 7.8 E. coli 0,03 <=1 >32 16 4 0,25 8 4 32 1 >64 <=16 <=2 <=1 pAmpC 
                 
                 Strain nr Species MER COL AMP CAZ CHL CIP CTX FFN FOX GEN NAL SMX TET TMP Presumptive phenotype 
EURL EC 7.1 E. coli S S R S S R S S S S R R R R Not resistant 
EURL EC 7.2 E. coli S S R R S S R S S S S R R R ESBL /Unusual phenotype 
EURL EC 7.3 E. coli S S R R S S R S R S S S S S pAmpC 
EURL EC 7.4 E. coli S S R R S S R S S S S S S S ESBL 
EURL EC 7.5 E. coli S S S S S S S S S S S S S S Not resistant 
EURL EC 7.6 E. coli S S R S R S S S S S S S R S Not resistant 
EURL EC 7.7 E. coli S S R S R S S R S R S R S R Not resistant 
EURL EC 7.8 E. coli S S R R S R R S R S R S S S pAmpC 
 
  Resistant 
Abbreviations: MER- meropenem, COL-colistin, AMP-ampicillin, CAZ-ceftazidime,  CHL-chloramphenicol, CIP- ciprofloxacin, CTX- cefotaxime, FFN- 
florfenicol, FOX- cefoxitine, GEN- gentamicin, NAL- nalidixic acid, SMX- sulphamethoxazol, TET- tetracycline, TMP- trimethroprim. 
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M00-06-001/01.12.2011  
EURL-AR External Quality Assurance System (EQAS) 2013: 
-Escherichia coli, staphylococci, enterococci and MRSA  
 
Id:  
Name of participant 
Address 
Country 
Lyngby, 17th June 2013 
 
Dear XX 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2013 Upon arrival to your 
laboratory, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-
AR EQAS are available: 
- Protocol for E. coli, staphylococci, enterococci and MRSA including test forms  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains  
 
We ask you to examine the eight E. coli, enterococci and S. aureus strains that we send to you 
by performing antimicrobial susceptibility testing and the eight S.aureus plus the two 
additional strains for MRSA. In the protocol you can find detailed description of the 
procedures to follow. Additionally, you can find a description of the procedure to enter your 
results into the interactive web database. For accessing the database, you need this username 
and password: 
 
Your username: xxx 
 
Your password: xxx 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
Results should be entered in the database no later than 6th September 2013. Please 
acknowledge receipt of this parcel immediately upon arrival (to licav@food.dtu.dk) and do not 
hesitate to contact me for further information. 
Yours sincerely, 
Lina Cavaco 
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PROTOCOL  
For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci, 
and identification and typing of MRSA 
 
 
1. INTRODUCTION    ................................................................................................................... 1
2. OBJECTIVES    .......................................................................................................................... 2
3. OUTLINE OF THE EC/ENT/STAPH EQAS 2013    ............................................................. 2
3.1 Shipping, receipt and storage of strains    ..................................................................... 2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains    ......... 2
3.3 Antimicrobial susceptibility testing    ............................................................................ 3
4. REPORTING OF RESULTS AND EVALUATION    ........................................................... 7
4.1 AST of E. coli, enterococci and staphylococci    ........................................................... 7
4.2 MRSA identification and typing    ................................................................................. 7
4.3 General recommendations for data upload    ............................................................... 7
5. HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE    ............................. 8
5.1 AST of E. coli, enterococci and staphylococci    ........................................................... 8
5.2 EQAS on identification and typing of MRSA    ........................................................... 9
 
1. INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci, and 
identification and typing of MRSA is among the tasks of the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph EQAS 2013 will include AST of eight E. 
coli, eight enterococci and eight staphylococci strains and AST of reference strains E. coli ATCC 
25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), S. aureus ATCC 25923 (CCM 3953) 
(for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) (for MIC). The above-mentioned 
reference strains are included in the parcel only for new participants of the EQAS who did not 
receive them previously. The reference strains are original CERTIFIED cultures provided free of 
charge, and should be used for future internal quality control for antimicrobial susceptibility testing 
in your laboratory. The reference strains will not be included in the years to come. Therefore, please 
take proper care of these strains. Handle and maintain them as suggested in the manual ‘Subculture 
and Maintenance of QC Strains’ available on the EURL-AR website (see www.eurl-ar.eu).  
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The strains included in the identification and typing of MRSA are the eight staphylococci strains for 
AST together with two additional Staphylococcus strains. This component of the EQAS functions 
as a continuation of the previous MRSA EQAS to evaluate the proficiency of the laboratories on 
procedures for confirmatory testing and spa typing.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
1. OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories, and to harmonise the breakpoints for antimicrobial susceptibility 
used within the EU. Additionally, with the MRSA confirmation and spa typing components 
included in this iteration, we intend to continue the harmonization and /or implementation process 
of MRSA monitoring at the NRL level. 
2. OUTLINE OF THE EC/ENT/STAPH EQAS 2013 
2.1. Shipping, receipt and storage of strains 
In June 2013, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and ten staphylococci strains from the 
National Food Institute, Denmark (two of the staphylococci strains are to be included in the MRSA 
components, only). This parcel will also contain reference strains, but only for participants who did 
not receive them previously. All strains belong to UN3373, Biological substance, category B. 
Extended spectrum beta-lactamase (ESBL)-producing strains as well as methicillin resistant 
Staphylococcus aureus (MRSA) will be included in the selected material.  
The reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the 
stab cultures must be subcultured, and all cultures should be kept refrigerated until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
2.2. Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
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2.3. Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below.
Participants performing minimum inhibitory concentration (MIC) determination should use the 
values listed in Tables 1, 2 and 3 for interpretation of results. These values represent the 
epidemiological cut-off values developed by EUCAST (
  
www.eucast.org), and allow categorisation 
of bacterial isolates into two categories: Resistant or susceptible. A categorisation as intermediate is 
not accepted, and intermediate results should be interpreted as susceptible.  
Participants using disk diffusion are recommended to interpret the results according to the 
breakpoints used routinely. However, when testing E. coli by disk diffusion, the interpretation of 
ciprofloxacin results should be done according to the guidelines described by Cavaco and Aarestrup 
in J Clin Microbiol. 2009 Sep;47(9):2751-8. Strains must be categorised resistant and susceptible. 
Also in this case, a categorization as intermediate is not accepted, and intermediate results should 
be interpreted as susceptible. 
 
E. coli  
Table 1: Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Ampicillin, AMP 8 
Cefepime 0.125 
Cefotaxime, CTX 0.25  
Cefoxitin, FOX 8 
Ceftazidime, CAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.06  
Colistin 2 
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Meropenem, MER 0.125 
Nalidixic acid, NAL 16 
Sulfonamides, SMX 64 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
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Plasmid-mediated quinolone resistance 
When performing antimicrobial susceptibility testing of E. coli, the interpretative criteria listed in 
Table 1 for results obtained by MIC-determination detect plasmid mediated quinolone resistant test 
strains. When interpreting a disk diffusion result, reference should be made to the guidelines in 
described by Cavaco and Aarestrup in J Clin Microbiol. 2009 Sep;47(9):2751-8. 
Beta-lactam resistance 
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(CTX), ceftazidime (CAZ) or meropenem. 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Resistance to cefepime gives further indication of ESBL production. 
Confirmatory test for carbapenemase production requires the testing of meropenem (MER).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that may be verified by PCR and sequencing. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating as: 
• Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and resistant 
to cefepime 
• Presumptive ESBL+pAmpC: -strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime 
• Presumptive pAmpC phenotype: -strains with negative synergy test. 
• Presumptive carbapenemase phenotype: -strain resistant to meropenem 
• Unusual phenotype: any other combinations 
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The EURL-AR aims to harmonise with the new EU monitoring and the EUCAST expert rules. 
Accordingly, MIC values and relative interpretation of cefotaxime, ceftazidime and meropenem 
used for detection of beta-lactamase-producing strains in this EQAS should be reported as found.  
 
Enterococci  
Table 2: Antimicrobials recommended for AST of Enterococcus spp. and interpretative criteria 
 
Antimicrobials for enterococci MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Teicoplanin 2 2 
Tetracycline, TET 4 4 
Tigecycline, TGC 0,25 Not applicable 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
 
Identification of the Enterococcus spp. 
In 2013, species identification of the Enterococci must be performed by the NRLs using in-house 
methods or adopting the protocol available on the EURL-AR website under: http://eurl-ar.eu/233-
protocols.htm.  
 
Staphylococci  
Eight of the staphylococci strains sent should be tested both in the AST component and in the 
MRSA components (EURL ST-7.1 to ST-7.8) whereas the two additional strains (EURL ST-7.9 
and 7.10) are intended for the MRSA EQAS components only. 
 
  
Appendix  4b  
Page 6 of 10 
EU Reference Laboratory for Antimicrobial Resistance                    
External Quality Assurance System (EQAS) 2013 
 
 
Page 6 of 10 
M00-06-001/21.06.2013 
Table 3: Antimicrobials recommended for AST of Staphylococcus aureus and interpretative criteria 
Antimicrobials for S. aureus MIC (µg/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Clindamycin, CLI 0.25 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 2 
Linezolid, LNZ 4 
Mupirocin, MUP 1 
Penicillin, PEN 0.125* 
Quinupristin-dalfopristin (Synercid), SYN 1 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 2 
Vancomycin 2 
*CLSI M100 Table 2C 
 
Identification and typing of MRSA 
All ten staphylococci (ST 7.1 to 7.10) are to be used in the MRSA identification and typing 
components of the proficiency test. Some test strains may be methicillin-resistant. Confirmation of 
mecA and/or mecC presence is mandatory in this EQAS. For this purpose, you are welcome to 
use the method you prefer, and upload the result as ‘positive’ or ‘negative’. According to CLSI 
recommendations (M100, Table 2C), all MRSA should be regarded as resistant to all β-lactam 
antibiotics. 
The ten staphylococci strains are either positive or negative for methicillin resistance and or, 
represent other methicillin susceptible or resistant Staphylococcus species. 
 
As part of the identification and typing of MRSA, handle the strains as follows:   
 
1. Take up the strains from the agar sticks and plate onto a blood agar plate (you may use 
additional selective media, but it is not compulsory).  
2. Incubate 24-48 h at 37 °C.  
3. Observe the colony morphology of the isolates on the blood agar plate (colour, appearance, 
haemolysis). Check for purity.  
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4. At this stage, the isolates should either be processed immediately or stored under appropriate 
conditions (–80°C) for later identification and characterisation. 
 
Identification of MRSA 
Presumptive MRSA isolates should be confirmed as Staphylococcus aureus isolates carrying the 
mecA gene or the mecC gene (previously known by mecALGA251) by PCR. There is no need to 
perform other screening methods (such as screening with either oxacillin or cefoxitin), thus, the 
presence of the mecA or mecC gene can be directly confirmed by PCR amplification. The species 
identification is simultaneously confirmed by using the EURL-AR recommended multiplex PCR 
protocol (http://eurl-ar.eu/233-protocols.htm) including the amplification of the spa gene (specific for 
Staphylococcus aureus species and may be sequenced for spa typing), the mecA-gene and the mecC 
gene (both encoding methicillin resistance) and the pvl gene (encoding the Panton Valentine 
Leukocidin).  
 
Spa typing  
Spa typing of the MRSA isolates may be performed additionally if the laboratory has the capacity to 
perform and analyse the spa-typing data. In case you decide to include spa types in the submitted 
data, these will be evaluated on the accuracy of the spa typing. 
 
 
3. REPORTING OF RESULTS AND EVALUATION 
3.1. AST of E. coli, enterococci and staphylococci 
 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range and/or antimicrobial 
disk content. Finally, if you did not use the cut-off values recommended in the protocol for 
interpretation of AST results, please report the breakpoints used in the database. 
3.2. MRSA identification and typing 
Fill in your results in the enclosed MRSA EQAS test forms. Please enter your results into the 
interactive web database. Please read the detailed description below before entering the web 
database. When you enter the results via the web, you will be guided through all steps on the screen 
and you will immediately be able to view and print a submission report of your results.  
3.3. General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than September, 6th 2013. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
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once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please return the completed test forms by e-
mail, fax or mail to the National Food Institute, Denmark.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact us: 
Lina Cavaco 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204 st room 51,  
DK-2800 Kgs. Lyngby 
Denmark 
Tel: +45 3588 6269 
Fax: +45 3588 6341 
E-mail: licav@food.dtu.dk 
 
4. HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2013 start web page (http://thor.dfvf.dk/crl), write your username and 
password in lower-cases and press enter. Your username and password are the same used in the 
previous EQAS’s arranged by The National Food Institute, Denmark. Do not hesitate to contact us 
if you experience problems with the login. 
You can browse back and forth by using the back and forward keys and by clicking on the EURL 
logo. 
4.1. AST of E. coli, enterococci and staphylococci 
Click on either “E. coli test results”, “enterococci test results” or “staphylococci test results” based 
on the results you are going to upload. The description reported below is based on Salmonella test 
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result entry, but it is the exact same procedure for entering E. coli, enterococci and staphylococci 
test results. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing of Salmonella 
and the brand of discs, tablets, MIC trays, etc.  
Fill in the fields related to either antimicrobial disk content or tested MIC range. If you used disk 
diffusion, please upload the breakpoints used for interpretation of results. 
Click on "save and go to next page”  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of methicillin 
resistance. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter the zone diameters in mm and MIC 
values in µg/ml. Remember to use the operator keys to show symbols like “equal to”, etc... If you 
do not use CLSI guidelines for AST of the reference strains, please add a comment on the method 
used. 
Click on "save and go to next page" 
This page is a menu that allows you to review the input pages and approve your input. 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
corrections. If you save a page without changes, you will see an error screen. In this case, click on 
"back" to get back to the page and "go to next page" to continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE! The approval blocks your data entry in the interactive 
database.  
4.2. EQAS on identification and typing of MRSA 
 
Click on “MRSA tests” to start entering your data regarding the MRSA EQAS. 
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Please read carefully the instructions on the webpage and start by answering to the questionnaire on 
the work performed in your laboratory relative to MRSA by clicking on “General MRSA 
questionnaire”.  
Please choose the options that more correctly describe your work on MRSA and before you leave 
this page, click on “Save page” which will take you back to the previous menu. Then, fill in the 
methods used in a second page by clicking on “Methods for MRSA test samples.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the confirmation of MRSA in this EQAS.  
Click on "Save and go to the next page”  
In the data entry pages for each strain, you enter the obtained results for each of the MRSA EQAS 
strains (EURL ST 7.1...7.10). 
If you wish to participate in the spa typing trial, you will have the option to include the spa-typing 
results. 
If you have performed the spa typing, choose the spa type from the list. If you did not perform spa 
typing, leave the field blank. In case the isolate is not a methicillin resistant Staphylococcus aureus, 
choose “not applicable (N/A)”. Click on "save and go to next page" to navigate to the next sample 
results, until you finish uploading all your data. 
From the last result sheet you get into the general menu, from where you can review the input 
pages: Browse through the pages and make corrections if necessary. Remember to save a page if 
you make any corrections. If you save a page without changes, you will see an error screen, and you 
just have to click on "back" to get back to the page and "go to next page" to continue. 
At the end, approve your input. Be sure that you have filled in all the results before approval, as 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database, but allows you to see and print the submitted results. 
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TEST FORMS 
 
Antimicrobial susceptibility testing of Escherichia coli, enterococci 
and staphylococci, and identification and typing of MRSA 
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
Which method did you use for antimicrobial susceptibility testing of enterococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs  
 Brand:                            
 
How many Enterococcus spp. isolates does your laboratory annually isolate:       
How many Enterococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility:       
Comments or additional information:       
 
 
Antimicrobial  General info 
 
The relevant information 
in the two columns below 
should be reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information 
only if you did not use the cut-off values 
recommended in the protocol  
 
Disk 
content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Ampicillin AMP              ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Daptomycin, DAP              ≤             ≥       
Erythromycin, ERY              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Linezolid, LZD              ≤             ≥       
Quin.-Dalf. (Synercid), SYN               ≤             ≥       
Teicoplanin, TEI             ≤             ≥       
Tetracycline, TET              ≤             ≥       
Tigecycline, TGC             ≤             ≥       
Vancomycin, VAN              ≤             ≥       
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TEST FORM                                                            
Which method did you use for antimicrobial susceptibility testing of staphylococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs 
 Brand:                            
 
How many Staphylococcus spp. isolates does your laboratory annually isolate:       
How many Staphylococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility:       
Comments or additional information:       
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information only 
if you did not use the cut-off values 
recommended in the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Cefoxitin, FOX              ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP              ≤             ≥       
Clindamycin, CLN             ≤             ≥       
Erythromycin, ERY              ≤             ≥       
Florfenicol, FFN              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Linezolid, LNZ             ≤             ≥       
Mupirocin, MUP             ≤             ≥       
Penicillin, PEN              ≤             ≥       
Quin.-Dalf. (Synercid), SYN               ≤             ≥       
Sulphonamides, SMX              ≤             ≥       
Tetracycline, TET              ≤             ≥       
Trimethoprim, TMP              ≤             ≥       
Vancomycin, VAN             ≤             ≥       
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TEST FORM       
Which method did you use for antimicrobial susceptibility testing of E. coli in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs 
 Brand:                            
 Incubation conditions:      °C/     h 
 
How many E. coli isolates does your laboratory annually isolate:       
How many E. coli isolates does your laboratory annually test for antimicrobial susceptibility:       
Comments or additional information:       
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
reported 
 
Zone diameter (mm) 
 
Please, report breakpoint information only 
if you did not use the cut-off values 
recommended in the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Susceptible 
(mm) 
 
Ampicillin, AMP                    ≤             ≥       
Cefotaxime, CTX              ≤             ≥       
Cefoxitin, FOX             ≤             ≥       
Ceftazidime, CAZ              ≤             ≥       
Ceftiofur, XNL              ≤             ≥       
Chloramphenicol, CHL              ≤             ≥       
Ciprofloxacin CIP                   ≤             ≥       
Colistin, COL             ≤             ≥       
Florfenicol, FFN              ≤             ≥       
Gentamicin, GEN              ≤             ≥       
Meropenem, MER             ≤             ≥       
Nalidixic acid, NAL              ≤             ≥       
Sulphonamides, SMX              ≤             ≥       
Tetracycline, TET              ≤             ≥       
Trimethoprim, TMP             ≤             ≥       
Appendix 4c    Examples of  Test forms                                                                                                        
Page 5 of 10 
 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
 
 
Page 5 of 10 
M00-06-001/21.06.2013 
TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
Enterococci 
 
EURL ENT. 
7.X 
 
 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
Enterococci 
 
EURL ENT. 
7.X 
 
 E. faecium 
 
 E. faecalis  
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
Vancomycin, VAN                    
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain Enterococcus faecalis ATCC 29212  
 
 
Strain  
 
 
 
Antimicrobial  
Zone diameter (mm) or 
MIC-value (μg/ml) 
E. faecalis  
ATCC 29212 
Ampicillin, AMP        
Chloramphenicol, CHL          
Ciprofloxacin, CIP          
Daptomycin, DAP       
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD        
Quinupristin-Dalfopristin (Synercid), SYN       
Teicoplanin, TEI       
Tetracycline, TET        
Tigecycline, TIG       
Vancomycin, VAN        
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TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter 
(mm) or 
MIC-value (μg/ml) 
S / R 
S. aureus 
 
EURL ST 7.X 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Florfenicol, FFN                    
Gentamicin, GEN                    
Linezolid, LNZ                   
Mupirocin, MUP                   
Penicillin, PEN                    
Quino-dalfo (Synercid), SYN                   
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive               Negative 
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain S. aureus ATCC 29213 (MIC) / 25923 (disk 
diffusion)  
 
 
Strain  
 
 
Antimicrobial  
 
Zone diameter (mm) or  
MIC-value (μg/ml) 
 
Please mark the tested strain 
 
   S. aureus ATCC 29213  
 
   S. aureus ATCC 25923 
Cefoxitin, FOX       
Chloramphenicol, CHL         
Ciprofloxacin, CIP         
Clindamycin       
Erythromycin, ERY        
Florfenicol, FFN        
Gentamicin, GEN        
Linezolid, LNZ       
Mupirocin, MUP       
Penicillin, PEN        
Quino-dalfo (Synercid), SYN       
Sulphonamides, SMX        
Tetracycline, TET        
Trimethoprim, TMP        
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TEST FORM                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
Zone diameter (mm) or 
MIC-value (μg/ml) 
S / R 
E. coli 
EURL EC 7.X 
Ampicillin, AMP                         
Cefotaxime, CTX                    
Ceftazidime, CAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Florfenicol, FFN                    
Gentamicin, GEN                    
Meropenem, MER                   
Nalidixic acid, NAL                    
Sulphonamides, SMX                    
Tetracycline, TET                    
Trimethoprim, TMP                    
All strains resistant to cefotaxime (CTX), ceftazidime (CAZ) or meropenem (MER) should be included for testing in 
the second panel confirmatory tests for ESBL or carbapenemase production. See further description of confirmatory 
tests in the protocol section ‘3.3 E. coli’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX MIC ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ MIC ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX MIC value   MIC value > 8   MIC value ≤ 8  Zone diameter  
 D ≤ 18 mm  
 D > 18 mm 
Cefepime, FEP MIC value  MIC value > 0,125  MIC value ≤ 0,125  Zone diameter  
 D ≤ 18 mm  
 D > 18 mm 
Imipenem, IMI MIC value   MIC value > 1   MIC value ≤ 1  Zone diameter  
 D ≤ 23 mm  
 D > 23 mm 
Ertapenem, ERP MIC 
value  
 MIC value > 1  
 MIC value ≤ 1  Zone diameter  
 D ≤ 22mm  
 D > 22 mm 
 Presumptive  ESBL 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 Presumptive carbapenemase 
 Unusual phenotype 
 
Comments (include genotype or other results):       
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TEST FORM                                                            
                                                           
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zone diameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Amoxicillin, AMX       
Ampicillin, AMP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin       
Florfenicol, FFN       
Gentamicin, GEN       
Meropenem       
Nalidixic acid, NAL       
Streptomycin, STR       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
Imipenem, IMI       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as representative 
for the sulfonamides concerning acceptable limits for quality control strains (CLSI M100, Table 3) 
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Impor tant Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
 Periodically perform colony counts to check the inoculum preparation procedure 
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
Appendix 4e, Page 3 of 4 
 
  
 
Subculture and Maintenance of QC strains                                                                                                     M00-06-001/01.09.2011  
Page 3 of 4 
 
 
DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
 Reference: CLSI M7-A8, page 45 
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Escherichia coli ATCC 25922 
Antimicrobial Disk diffusion MIC 
Ampicillin, AMP 16 - 22 2 - 8 
Cefotaxime, CTX 29 - 35 0.03 - 0.12 
Cefoxitin, FOX 23-29 2-8 
Ceftazidime, CAZ 25 - 32 0.06 - 0.5 
Chloramphenicol, CHL 21 - 27 2 - 8 
Ciprofloxacin, CIP 30 - 40 0.004 - 0.015 
Colistin, COL 11-17 0,25-2 
Florfenicol, FFN 22-28 2-8 
Gentamicin, GEN 19 - 26 0.25 - 1 
Meropenem, MER 28-34 0.008-0.06 
Nalidixic acid, NAL 22 - 28 1 - 4 
Sulphonamides, SMX 15 - 23 8 - 32 
Tetracycline, TET 18 - 25 0.5 - 2 
Trimethoprim, TMP 21 - 28 0.5 - 2 
 
Enterococcus faecalis ATCC 29212- MIC method 
Antimicrobial Low limit High limit 
Ampicillin , AMP 0,5 2 
Chloramphenicol, CHL 4 16 
Ciprofloxacin , CIP 0,25 2 
Daptomycin, DAP 1 4 
Erythromycin, ERY 1 4 
Gentamicin, GEN 4 16 
Linezolid, LZD 1 4 
Quinu-dalfo-pristin, Q-D 2 8 
Teicoplanin, TEI 0,25 1 
Tetracycline, TET 8 32 
Tigecycline, TIG 0,03 0,12 
Vancomycin, VAN 1 4 
  
Staphylococcus aureus ATCC 29213- MIC method 
Antimicrobial Low limit High limit 
Cefoxitin, FOX 1 4 
Chloramphenicol, CHL 2 16 
Ciprofloxacin, CIP 0,12 0,5 
Clindamycin, CLN 0,06 0,25 
Erythromycin, ERY 0,25 1 
Florfenicol, FFN 2 8 
Gentamicin, GEN 0,12 1 
Linezolid, LZD 1 4 
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Mupirocin, MUP   
Penicillin, PEN 0,25 2 
Quinupristin-
dalfopristin, SYN 
0,25 1 
Tetracycline, TET 0,12 1 
Trimethoprim, TMP 1 4 
Vancomycin, VAN 0,5 2 
 
 
Staphylococcus aureus ATCC 25923- Disk Diffusion 
Antimicrobial Concentration Low limit High limit 
Cefoxitin, FOX 30 23 29 
Chloramphenicol, CHL 30 19 26 
Ciprofloxacin, CIP 5 22 30 
Clindamycin, CLN 2 24 30 
Erythromycin, ERY 15 22 30 
Florfenicol, FFN 30 22 29 
Gentamicin, GEN 10 19 27 
Linezolid, LZD 30 25 32 
Mupirocin, MUP Na   
Penicillin, PEN 10 26 37 
Quinupristin-dalfopristin, SYN 15 21 28 
Sulfisoxazole, FIS 250-300 24 34 
Tetracycline, TET 30 24 30 
Trimethroprim, TMP 5 19 26 
Vancomycin, VAN 30 17 21 
 
S. aureus ATCC 25923 – Rosco tablets 
Antimicrobial Concentration Low limit High limit 
Cefoxitin, FOX 30 23 29 
Chloramphenicol, CHL 30 19 26 
Ciprofloxacin, CIP 5 22 30 
Clindamycin CLN 2 24 30 
Erythromycin, ERY 15 22 30 
Florfenicol, FFN na 0 256 
Gentamicin, GEN 10 19 27 
Linezolid, LZD 30 25 32 
Mupirocin, MUP 10 21 26 
Quinupristin-dalfopristin, SYN 15 21 28 
Sulfisoxazole, FIS 240 23 33 
Tetracycline, TET 30 24 30 
Trimethoprim, TMP 5 19 26 
Vancomycin, VAN 30 17 21 
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Appendix 6a- Test results from reference strain Enterococcus faecalis ATCC 29212 
 
Lab no Antib Operator Value Low limit High limit Mark Method 
1 Ampicillin , AMP <= 2 0.5 2 1 MIC 
1 Chloramphenicol, CHL = 4 4 16 1 MIC 
1 Ciprofloxacin , CIP <= 0.5 0.25 2 1 MIC 
1 Erythromycin, ERY = 1 1 4 1 MIC 
1 Gentamicin, GEN <= 16 4 16 1 MIC 
1 Linezolid, LZD = 1 1 4 1 MIC 
1 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
1 Teicoplanin, TEI <= 0.25 0.25 1 1 MIC 
1 Tetracycline, TET = 16 8 32 1 MIC 
1 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
1 Vancomycin, VAN = 2 1 4 1 MIC 
2 Ampicillin , AMP = 1 0.5 2 1 MIC 
2 Chloramphenicol, CHL = 8 4 16 1 MIC 
2 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
2 Daptomycin, DAP = 2 1 4 1 MIC 
2 Erythromycin, ERY = 2 1 4 1 MIC 
2 Gentamicin, GEN = 8 4 16 1 MIC 
2 Linezolid, LZD = 2 1 4 1 MIC 
2 Teicoplanin, TEI <= 0.25 0.25 1 1 MIC 
2 Tetracycline, TET = 16 8 32 1 MIC 
2 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
2 Vancomycin, VAN = 2 1 4 1 MIC 
6 Chloramphenicol, CHL = 8 4 16 1 MIC 
6 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
6 Daptomycin, DAP = 2 1 4 1 MIC 
6 Erythromycin, ERY = 1 1 4 1 MIC 
6 Linezolid, LZD = 2 1 4 1 MIC 
6 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
6 Tetracycline, TET = 16 8 32 1 MIC 
6 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
6 Vancomycin, VAN = 4 1 4 1 MIC 
9 Ampicillin , AMP = 1 0.5 2 1 MIC 
9 Chloramphenicol, CHL = 8 4 16 1 MIC 
9 Ciprofloxacin , CIP = 0.5 0.25 2 1 MIC 
9 Erythromycin, ERY = 2 1 4 1 MIC 
9 Gentamicin, GEN = 8 4 16 1 MIC 
9 Linezolid, LZD = 2 1 4 1 MIC 
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Lab no Antib Operator Value Low limit High limit Mark Method 
9 Quin.-Dalf. (Synercid), SYN = 4 2 8 1 MIC 
9 Tetracycline, TET = 16 8 32 1 MIC 
9 Vancomycin, VAN = 2 1 4 1 MIC 
11 Ampicillin , AMP = 0.5 0.5 2 1 MIC 
11 Chloramphenicol, CHL = 4 4 16 1 MIC 
11 Erythromycin, ERY = 2 1 4 1 MIC 
11 Gentamicin, GEN = 8 4 16 1 MIC 
11 Linezolid, LZD = 1 1 4 1 MIC 
11 Tetracycline, TET = 16 8 32 1 MIC 
11 Vancomycin, VAN <= 1 1 4 1 MIC 
12 Ampicillin , AMP = 1 0.5 2 1 MIC 
12 Chloramphenicol, CHL = 8 4 16 1 MIC 
12 Erythromycin, ERY = 4 1 4 1 MIC 
12 Gentamicin, GEN = 8 4 16 1 MIC 
12 Linezolid, LZD = 2 1 4 1 MIC 
12 Tetracycline, TET = 16 8 32 1 MIC 
12 Vancomycin, VAN = 2 1 4 1 MIC 
16 Ampicillin , AMP = 1 0.5 2 1 MIC 
16 Chloramphenicol, CHL = 8 4 16 1 MIC 
16 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
16 Daptomycin, DAP = 2 1 4 1 MIC 
16 Erythromycin, ERY = 2 1 4 1 MIC 
16 Gentamicin, GEN = 16 4 16 1 MIC 
16 Linezolid, LZD = 2 1 4 1 MIC 
16 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
16 Tetracycline, TET = 32 8 32 1 MIC 
16 Tigecycline, TGC = 0.25 0.03 0.12 0 MIC 
16 Vancomycin, VAN = 4 1 4 1 MIC 
17 Ampicillin , AMP = 1 0.5 2 1 MIC 
17 Chloramphenicol, CHL = 8 4 16 1 MIC 
17 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
17 Erythromycin, ERY = 1 1 4 1 MIC 
17 Gentamicin, GEN = 16 4 16 1 MIC 
17 Linezolid, LZD = 2 1 4 1 MIC 
17 Quin.-Dalf. (Synercid), SYN = 4 2 8 1 MIC 
17 Tetracycline, TET = 16 8 32 1 MIC 
17 Vancomycin, VAN = 4 1 4 1 MIC 
20 Ampicillin , AMP = 2 0.5 2 1 MIC 
20 Chloramphenicol, CHL = 16 4 16 1 MIC 
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Lab no Antib Operator Value Low limit High limit Mark Method 
20 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
20 Erythromycin, ERY = 2 1 4 1 MIC 
20 Gentamicin, GEN = 8 4 16 1 MIC 
20 Linezolid, LZD = 2 1 4 1 MIC 
20 Quin.-Dalf. (Synercid), SYN = 4 2 8 1 MIC 
20 Tetracycline, TET = 32 8 32 1 MIC 
20 Vancomycin, VAN = 2 1 4 1 MIC 
21 Chloramphenicol, CHL = 4 4 16 1 MIC 
21 Ciprofloxacin , CIP = 2 0.25 2 1 MIC 
21 Erythromycin, ERY = 1 1 4 1 MIC 
21 Gentamicin, GEN = 8 4 16 1 MIC 
21 Linezolid, LZD = 2 1 4 1 MIC 
21 Quin.-Dalf. (Synercid), SYN = 4 2 8 1 MIC 
21 Tetracycline, TET = 32 8 32 1 MIC 
22 Ampicillin , AMP = 1 0.5 2 1 MIC 
22 Chloramphenicol, CHL = 8 4 16 1 MIC 
22 Erythromycin, ERY = 2 1 4 1 MIC 
22 Gentamicin, GEN = 8 4 16 1 MIC 
22 Linezolid, LZD = 2 1 4 1 MIC 
22 Tetracycline, TET = 16 8 32 1 MIC 
22 Vancomycin, VAN = 2 1 4 1 MIC 
23 Chloramphenicol, CHL = 8 4 16 1 MIC 
23 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
23 Erythromycin, ERY = 2 1 4 1 MIC 
23 Tetracycline, TET = 32 8 32 1 MIC 
23 Vancomycin, VAN = 4 1 4 1 MIC 
25 Ampicillin , AMP <= 1 0.5 2 1 MIC 
25 Chloramphenicol, CHL = 8 4 16 1 MIC 
25 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
25 Erythromycin, ERY = 4 1 4 1 MIC 
25 Gentamicin, GEN = 16 4 16 1 MIC 
25 Linezolid, LZD = 2 1 4 1 MIC 
25 Quin.-Dalf. (Synercid), SYN = 16 2 8 0 MIC 
25 Tetracycline, TET = 32 8 32 1 MIC 
25 Vancomycin, VAN = 4 1 4 1 MIC 
26 Chloramphenicol, CHL = 8 4 16 1 MIC 
26 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
26 Daptomycin, DAP = 4 1 4 1 MIC 
26 Erythromycin, ERY = 1 1 4 1 MIC 
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Lab no Antib Operator Value Low limit High limit Mark Method 
26 Gentamicin, GEN <= 128 4 16 1 MIC 
26 Linezolid, LZD = 2 1 4 1 MIC 
26 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
26 Tetracycline, TET = 16 8 32 1 MIC 
26 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
26 Vancomycin, VAN = 4 1 4 1 MIC 
29 Ampicillin , AMP = 1 0.5 2 1 MIC 
29 Chloramphenicol, CHL = 4 4 16 1 MIC 
29 Erythromycin, ERY = 4 1 4 1 MIC 
29 Gentamicin, GEN = 4 4 16 1 MIC 
29 Tetracycline, TET = 16 8 32 1 MIC 
29 Vancomycin, VAN = 2 1 4 1 MIC 
30 Ampicillin , AMP = 1 0.5 2 1 MIC 
30 Chloramphenicol, CHL = 8 4 16 1 MIC 
30 Ciprofloxacin , CIP <= 1 0.25 2 1 MIC 
30 Daptomycin, DAP = 2 1 4 1 MIC 
30 Erythromycin, ERY = 2 1 4 1 MIC 
30 Gentamicin, GEN = 8 4 16 1 MIC 
30 Linezolid, LZD = 2 1 4 1 MIC 
30 Quin.-Dalf. (Synercid), SYN >  4 2 8 1 MIC 
30 Tetracycline, TET >  16 8 32 1 MIC 
30 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
30 Vancomycin, VAN = 2 1 4 1 MIC 
32 Chloramphenicol, CHL = 8 4 16 1 MIC 
32 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
32 Daptomycin, DAP = 2 1 4 1 MIC 
32 Erythromycin, ERY = 1 1 4 1 MIC 
32 Gentamicin, GEN <= 128 4 16 1 MIC 
32 Linezolid, LZD = 2 1 4 1 MIC 
32 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
32 Tetracycline, TET = 16 8 32 1 MIC 
32 Tigecycline, TGC = 0.06 0.03 0.12 1 MIC 
32 Vancomycin, VAN = 4 1 4 1 MIC 
33 Ampicillin , AMP = 1 0.5 2 1 MIC 
33 Chloramphenicol, CHL = 4 4 16 1 MIC 
33 Erythromycin, ERY = 2 1 4 1 MIC 
33 Gentamicin, GEN = 8 4 16 1 MIC 
33 Linezolid, LZD = 2 1 4 1 MIC 
33 Tetracycline, TET = 32 8 32 1 MIC 
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Lab no Antib Operator Value Low limit High limit Mark Method 
33 Vancomycin, VAN = 2 1 4 1 MIC 
34 Ampicillin , AMP = 1 0.5 2 1 MIC 
34 Chloramphenicol, CHL = 8 4 16 1 MIC 
34 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
34 Erythromycin, ERY = 1 1 4 1 MIC 
34 Gentamicin, GEN = 8 4 16 1 MIC 
34 Linezolid, LZD = 2 1 4 1 MIC 
34 Quin.-Dalf. (Synercid), SYN >  4 2 8 1 MIC 
34 Tetracycline, TET = 32 8 32 1 MIC 
34 Vancomycin, VAN = 4 1 4 1 MIC 
36 Ampicillin , AMP = 1 0.5 2 1 MIC 
36 Chloramphenicol, CHL = 4 4 16 1 MIC 
36 Erythromycin, ERY = 4 1 4 1 MIC 
36 Gentamicin, GEN = 8 4 16 1 MIC 
36 Linezolid, LZD = 1 1 4 1 MIC 
36 Tetracycline, TET = 32 8 32 1 MIC 
36 Vancomycin, VAN <= 1 1 4 1 MIC 
37 Ampicillin , AMP = 1 0.5 2 1 AGA 
37 Chloramphenicol, CHL = 4 4 16 1 AGA 
37 Ciprofloxacin , CIP = 0.5 0.25 2 1 AGA 
37 Erythromycin, ERY = 1 1 4 1 AGA 
37 Gentamicin, GEN = 4 4 16 1 AGA 
37 Tetracycline, TET = 16 8 32 1 AGA 
37 Vancomycin, VAN = 2 1 4 1 AGA 
39 Ampicillin , AMP = 1 0.5 2 1 MIC 
39 Chloramphenicol, CHL = 4 4 16 1 MIC 
39 Erythromycin, ERY = 1 1 4 1 MIC 
39 Gentamicin, GEN = 4 4 16 1 MIC 
39 Linezolid, LZD <= 0.5 1 4 0 MIC 
39 Tetracycline, TET = 16 8 32 1 MIC 
39 Vancomycin, VAN = 2 1 4 1 MIC 
40 Ampicillin , AMP = 22  None  None * DD 
40 Chloramphenicol, CHL = 24  None  None * DD 
40 Ciprofloxacin , CIP = 23  None  None * DD 
40 Erythromycin, ERY = 23  None  None * DD 
40 Linezolid, LZD = 24  None  None * DD 
40 Tetracycline, TET = 19  None  None * DD 
40 Vancomycin, VAN = 20  None  None * DD 
41 Ampicillin , AMP = 1 0.5 2 1 MIC 
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Lab no Antib Operator Value Low limit High limit Mark Method 
41 Chloramphenicol, CHL = 8 4 16 1 MIC 
41 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
41 Daptomycin, DAP = 2 1 4 1 MIC 
41 Erythromycin, ERY = 1 1 4 1 MIC 
41 Gentamicin, GEN = 8 4 16 1 MIC 
41 Linezolid, LZD = 2 1 4 1 MIC 
41 Quin.-Dalf. (Synercid), SYN = 2 2 8 1 MIC 
41 Tetracycline, TET = 8 8 32 1 MIC 
41 Tigecycline, TGC = 0.12 0.03 0.12 1 MIC 
41 Vancomycin, VAN = 2 1 4 1 MIC 
42 Ampicillin , AMP <= 2 0.5 2 1 MIC 
42 Chloramphenicol, CHL = 8 4 16 1 MIC 
42 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
42 Erythromycin, ERY = 2 1 4 1 MIC 
42 Gentamicin, GEN <= 128 4 16 1 MIC 
42 Linezolid, LZD = 2 1 4 1 MIC 
42 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
42 Tetracycline, TET = 16 8 32 1 MIC 
42 Vancomycin, VAN = 4 1 4 1 MIC 
45 Ampicillin , AMP = 26.2  None  None * DD 
45 Chloramphenicol, CHL = 21.5  None  None * DD 
45 Ciprofloxacin , CIP = 21.7  None  None * DD 
45 Erythromycin, ERY = 18.1  None  None * DD 
45 Gentamicin, GEN = 12.1  None  None * DD 
45 Linezolid, LZD = 24.3  None  None * DD 
45 Teicoplanin, TEI = 17.3  None  None * DD 
45 Tetracycline, TET = 12.3  None  None * DD 
45 Tigecycline, TGC = 20.1  None  None * DD 
45 Vancomycin, VAN = 17.6  None  None  DD 
46 Ampicillin , AMP >  8 0.5 2 0 AGA 
46 Chloramphenicol, CHL = 4 4 16 1 AGA 
46 Ciprofloxacin , CIP = 8 0.25 2 0 AGA 
46 Daptomycin, DAP = 4 1 4 1 AGA 
46 Erythromycin, ERY = 1 1 4 1 AGA 
46 Gentamicin, GEN = 8 4 16 1 AGA 
46 Linezolid, LZD = 2 1 4 1 AGA 
46 Quin.-Dalf. (Synercid), SYN = 2 2 8 1 AGA 
46 Teicoplanin, TEI >  32 0.25 1 0 AGA 
46 Tetracycline, TET >  8 8 32 1 AGA 
  
Appendix 6a, Page 7 of 7 
 
 
Lab no Antib Operator Value Low limit High limit Mark Method 
46 Tigecycline, TGC = 0.032 0.03 0.12 1 AGA 
46 Vancomycin, VAN >  32 1 4 0 AGA 
58 Ampicillin , AMP = 1 0.5 2 1 MIC 
58 Chloramphenicol, CHL = 8 4 16 1 MIC 
58 Ciprofloxacin , CIP = 1 0.25 2 1 MIC 
58 Daptomycin, DAP = 2 1 4 1 MIC 
58 Erythromycin, ERY = 2 1 4 1 MIC 
58 Gentamicin, GEN = 8 4 16 1 MIC 
58 Linezolid, LZD = 2 1 4 1 MIC 
58 Quin.-Dalf. (Synercid), SYN = 8 2 8 1 MIC 
58 Tetracycline, TET = 16 8 32 1 MIC 
58 Tigecycline, TGC = 0.12 0.03 0.12 1 MIC 
58 Vancomycin, VAN = 4 1 4 1 MIC 
• CLSI has not published a QC ranges for DD of strain ATCC 29212, therefore the results 
submitted by the laboratories using DD were not evaluated. 
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Appendix 6b- Test results from QC reference strain Staphylococcus aureus 
 
 Test results from reference strain Staphylococcus aureus ATCC 29213-MIC 
 
Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
1 Cefoxitin, FOX = 2 1 4 1 MIC 
1 Chloramphenicol, CHL = 8 2 16 1 MIC 
1 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
1 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
1 Florfenicol, FFN = 4 2 8 1 MIC 
1 Gentamicin, GEN <= 0.25 0.12 1 1 MIC 
1 Penicillin, PEN = 0.5 0.25 2 1 MIC 
1 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
1 Trimethoprim, TMP = 1 1 4 1 MIC 
2 Cefoxitin, FOX = 4 1 4 1 MIC 
2 Chloramphenicol, CHL = 8 2 16 1 MIC 
2 Ciprofloxacin, CIP <= 0.25 0.12 0.5 1 MIC 
2 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
2 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
2 Gentamicin, GEN <= 1 0.12 1 1 MIC 
2 Linezolid, LZD = 2 1 4 1 MIC 
2 Mupirocin, MUP <= 0.5 0 256 1 MIC 
2 Penicillin, PEN = 0.5 0.25 2 1 MIC 
2 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
2 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
2 Trimethoprim, TMP <= 2 1 4 1 MIC 
2 Vancomycin, VAN <= 1 0.5 2 1 MIC 
6 Cefoxitin, FOX = 2 1 4 1 MIC 
6 Chloramphenicol, CHL = 8 2 16 1 MIC 
6 Ciprofloxacin, CIP <  0.25 0.12 0.5 1 MIC 
6 Clindamycin, CLN = 0.12 0.06 0.25 1 MIC 
6 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
6 Gentamicin, GEN <  1 0.12 1 1 MIC 
6 Linezolid, LZD = 2 1 4 1 MIC 
6 Mupirocin, MUP <  0.5 0 256 1 MIC 
6 Penicillin, PEN = 0.25 0.25 2 1 MIC 
6 Quin.-Dalf. (Synercid), SYN <  0.5 0.25 1 1 MIC 
6 Sulfisoxazole, FIS <  64 32 128 1 MIC 
6 Tetracycline, TET <  0.5 0.12 1 1 MIC 
6 Trimethoprim, TMP <  2 1 4 1 MIC 
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Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
6 Vancomycin, VAN <  1 0.5 2 1 MIC 
9 Cefoxitin, FOX = 4 1 4 1 MIC 
9 Chloramphenicol, CHL = 4 2 16 1 MIC 
9 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
9 Clindamycin, CLN = 0.12 0.06 0.25 1 MIC 
9 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
9 Florfenicol, FFN = 4 2 8 1 MIC 
9 Gentamicin, GEN = 1 0.12 1 1 MIC 
9 Linezolid, LZD = 2 1 4 1 MIC 
9 Penicillin, PEN = 0.5 0.25 2 1 MIC 
9 Quin.-Dalf. (Synercid), SYN = 0.5 0.25 1 1 MIC 
9 Sulfisoxazole, FIS = 64 32 128 1 MIC 
9 Tetracycline, TET = 0.5 0.12 1 1 MIC 
9 Trimethoprim, TMP = 2 1 4 1 MIC 
9 Vancomycin, VAN = 1 0.5 2 1 MIC 
11 Chloramphenicol, CHL = 8 2 16 1 MIC 
11 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
11 Clindamycin, CLN <= 0.25 0.06 0.25 1 MIC 
11 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
11 Gentamicin, GEN <= 0.5 0.12 1 1 MIC 
11 Penicillin, PEN = 1 0.25 2 1 MIC 
11 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
11 Trimethoprim, TMP = 2 1 4 1 MIC 
12 Cefoxitin, FOX = 4 1 4 1 MIC 
12 Chloramphenicol, CHL = 8 2 16 1 MIC 
12 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
12 Clindamycin, CLN <= 0.25 0.06 0.25 1 MIC 
12 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
12 Gentamicin, GEN <= 0.5 0.12 1 1 MIC 
12 Penicillin, PEN = 0.5 0.25 2 1 MIC 
12 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
12 Trimethoprim, TMP = 2 1 4 1 MIC 
17 Cefoxitin, FOX = 4 1 4 1 MIC 
17 Chloramphenicol, CHL = 8 2 16 1 MIC 
17 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
17 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
17 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
17 Gentamicin, GEN <= 1 0.12 1 1 MIC 
17 Linezolid, LZD = 4 1 4 1 MIC 
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Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
17 Mupirocin, MUP <= 0.5 0 256 1 MIC 
17 Penicillin, PEN = 1 0.25 2 1 MIC 
17 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
17 Sulfisoxazole, FIS <= 64 32 128 1 MIC 
17 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
17 Trimethoprim, TMP = 4 1 4 1 MIC 
17 Vancomycin, VAN <= 1 0.5 2 1 MIC 
19 Cefoxitin, FOX = 2 1 4 1 MIC 
19 Chloramphenicol, CHL = 8 2 16 1 MIC 
19 Ciprofloxacin, CIP <= 0.25 0.12 0.5 1 MIC 
19 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
19 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
19 Gentamicin, GEN <= 1 0.12 1 1 MIC 
19 Linezolid, LZD = 2 1 4 1 MIC 
19 Mupirocin, MUP <= 0.5 0 256 1 MIC 
19 Penicillin, PEN = 0.25 0.25 2 1 MIC 
19 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
19 Sulfisoxazole, FIS <= 64 32 128 1 MIC 
19 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
19 Trimethoprim, TMP <= 2 1 4 1 MIC 
19 Vancomycin, VAN <= 1 0.5 2 1 MIC 
20 Cefoxitin, FOX = 2 1 4 1 MIC 
20 Chloramphenicol, CHL = 16 2 16 1 MIC 
20 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
20 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
20 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
20 Florfenicol, FFN <= 8 2 8 1 MIC 
20 Gentamicin, GEN <= 1 0.12 1 1 MIC 
20 Linezolid, LZD = 2 1 4 1 MIC 
20 Mupirocin, MUP <= 0.5 0 256 1 MIC 
20 Penicillin, PEN = 0.25 0.25 2 1 MIC 
20 Quin.-Dalf. (Synercid), SYN = 1 0.25 1 1 MIC 
20 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
20 Trimethoprim, TMP <= 2 1 4 1 MIC 
20 Vancomycin, VAN <= 1 0.5 2 1 MIC 
21 Cefoxitin, FOX = 2 1 4 1 MIC 
21 Chloramphenicol, CHL = 8 2 16 1 MIC 
21 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
21 Clindamycin, CLN = 0.12 0.06 0.25 1 MIC 
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21 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
21 Gentamicin, GEN = 1 0.12 1 1 MIC 
21 Linezolid, LZD = 2 1 4 1 MIC 
21 Mupirocin, MUP = 0.5 0 256 1 MIC 
21 Penicillin, PEN = 0.25 0.25 2 1 MIC 
21 Quin.-Dalf. (Synercid), SYN = 0.5 0.25 1 1 MIC 
21 Sulfisoxazole, FIS = 64 32 128 1 MIC 
21 Tetracycline, TET = 0.5 0.12 1 1 MIC 
21 Trimethoprim, TMP = 2 1 4 1 MIC 
21 Vancomycin, VAN = 1 0.5 2 1 MIC 
22 Cefoxitin, FOX = 2 1 4 1 MIC 
22 Chloramphenicol, CHL = 8 2 16 1 MIC 
22 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
22 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
22 Gentamicin, GEN = 1 0.12 1 1 MIC 
22 Penicillin, PEN = 0.5 0.25 2 1 MIC 
22 Tetracycline, TET = 1 0.12 1 1 MIC 
22 Trimethoprim, TMP = 2 1 4 1 MIC 
23 Cefoxitin, FOX = 4 1 4 1 MIC 
23 Chloramphenicol, CHL = 8 2 16 1 MIC 
23 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
23 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
23 Gentamicin, GEN <  1 0.12 1 1 MIC 
23 Penicillin, PEN = 0.25 0.25 2 1 MIC 
23 Sulfisoxazole, FIS <  64 32 128 1 MIC 
23 Tetracycline, TET <  0.5 0.12 1 1 MIC 
23 Trimethoprim, TMP <  2 1 4 1 MIC 
25 Clindamycin, CLN = 0.25 0.06 0.25 1 MIC 
25 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
25 Penicillin, PEN = 1 0.25 2 1 MIC 
25 Tetracycline, TET = 0.5 0.12 1 1 MIC 
26 Cefoxitin, FOX = 2 1 4 1 MIC 
26 Chloramphenicol, CHL = 8 2 16 1 MIC 
26 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
26 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
26 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
26 Florfenicol, FFN = 4 2 8 1 MIC 
26 Gentamicin, GEN = 0.5 0.12 1 1 MIC 
26 Linezolid, LZD = 2 1 4 1 MIC 
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26 Mupirocin, MUP <= 0.5 0 256 1 MIC 
26 Penicillin, PEN = 0.25 0.25 2 1 MIC 
26 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
26 Sulfisoxazole, FIS <= 32 32 128 1 MIC 
26 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
26 Trimethoprim, TMP = 1 1 4 1 MIC 
26 Vancomycin, VAN <= 1 0.5 2 1 MIC 
29 Chloramphenicol, CHL = 2 2 16 1 MIC 
29 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
29 Erythromycin, ERY = 0.25 0.25 1 1 MIC 
29 Gentamicin, GEN = 0.5 0.12 1 1 MIC 
29 Penicillin, PEN = 0.5 0.25 2 1 MIC 
29 Tetracycline, TET = 0.5 0.12 1 1 MIC 
29 Trimethoprim, TMP = 1 1 4 1 MIC 
30 Cefoxitin, FOX = 4 1 4 1 MIC 
30 Chloramphenicol, CHL = 8 2 16 1 MIC 
30 Ciprofloxacin, CIP <= 0.25 0.12 0.5 1 MIC 
30 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
30 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
30 Gentamicin, GEN <= 1 0.12 1 1 MIC 
30 Linezolid, LZD = 2 1 4 1 MIC 
30 Mupirocin, MUP <= 0.5 0 256 1 MIC 
30 Penicillin, PEN = 0.25 0.25 2 1 MIC 
30 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
30 Sulfisoxazole, FIS <= 64 32 128 1 MIC 
30 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
30 Trimethoprim, TMP <= 2 1 4 1 MIC 
30 Vancomycin, VAN <= 1 0.5 2 1 MIC 
31 Cefoxitin, FOX <= 4 1 4 1 MIC 
31 Chloramphenicol, CHL <= 16 2 16 1 MIC 
31 Ciprofloxacin, CIP <= 0.12 0.12 0.5 1 MIC 
31 Clindamycin, CLN <= 0.25 0.06 0.25 1 MIC 
31 Erythromycin, ERY <= 0.5 0.25 1 1 MIC 
31 Florfenicol, FFN <= 8 2 8 1 MIC 
31 Gentamicin, GEN <= 2 0.12 1 1 MIC 
31 Linezolid, LZD <= 2 1 4 1 MIC 
31 Mupirocin, MUP <= 1 0 256 1 MIC 
31 Penicillin, PEN <= 0.5 0.25 2 1 MIC 
31 Quin.-Dalf. (Synercid), SYN <= 1 0.25 1 1 MIC 
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31 Sulfisoxazole, FIS <= 128 32 128 1 MIC 
31 Tetracycline, TET <= 1 0.12 1 1 MIC 
31 Trimethoprim, TMP <= 2 1 4 1 MIC 
31 Vancomycin, VAN <= 1 0.5 2 1 MIC 
33 Cefoxitin, FOX = 4 1 4 1 MIC 
33 Chloramphenicol, CHL = 8 2 16 1 MIC 
33 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
33 Clindamycin, CLN <= 0.25 0.06 0.25 1 MIC 
33 Erythromycin, ERY = 1 0.25 1 1 MIC 
33 Gentamicin, GEN = 1 0.12 1 1 MIC 
33 Penicillin, PEN = 1 0.25 2 1 MIC 
33 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
33 Trimethoprim, TMP = 2 1 4 1 MIC 
34 Cefoxitin, FOX = 4 1 4 1 MIC 
34 Chloramphenicol, CHL = 16 2 16 1 MIC 
34 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
34 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
34 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
34 Gentamicin, GEN <= 1 0.12 1 1 MIC 
34 Linezolid, LZD = 4 1 4 1 MIC 
34 Mupirocin, MUP <= 0.5 0 256 1 MIC 
34 Penicillin, PEN = 1 0.25 2 1 MIC 
34 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
34 Sulfisoxazole, FIS <= 64 32 128 1 MIC 
34 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
34 Trimethoprim, TMP <= 2 1 4 1 MIC 
34 Vancomycin, VAN <= 1 0.5 2 1 MIC 
35 Cefoxitin, FOX = 4 1 4 1 MIC 
36 Chloramphenicol, CHL = 4 2 16 1 MIC 
36 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 MIC 
36 Clindamycin, CLN <= 0.25 0.06 0.25 1 MIC 
36 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
36 Gentamicin, GEN = 1 0.12 1 1 MIC 
36 Penicillin, PEN = 1 0.25 2 1 MIC 
36 Tetracycline, TET = 1 0.12 1 1 MIC 
36 Trimethoprim, TMP = 2 1 4 1 MIC 
37 Cefoxitin, FOX = 4 1 4 1 AGA 
37 Chloramphenicol, CHL = 4 2 16 1 AGA 
37 Ciprofloxacin, CIP = 0.25 0.12 0.5 1 AGA 
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37 Erythromycin, ERY = 0.5 0.25 1 1 AGA 
37 Gentamicin, GEN = 0.25 0.12 1 1 AGA 
37 Penicillin, PEN = 0.25 0.25 2 1 AGA 
37 Tetracycline, TET = 0.25 0.12 1 1 AGA 
37 Trimethoprim, TMP = 1 1 4 1 AGA 
39 Chloramphenicol, CHL = 8 2 16 1 MIC 
39 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
39 Clindamycin, CLN = 8 0.06 0.25 0 MIC 
39 Erythromycin, ERY = 1 0.25 1 1 MIC 
39 Gentamicin, GEN = 1 0.12 1 1 MIC 
39 Penicillin, PEN = 1 0.25 2 1 MIC 
39 Tetracycline, TET = 1 0.12 1 1 MIC 
39 Trimethoprim, TMP = 2 1 4 1 MIC 
41 Cefoxitin, FOX = 4 1 4 1 MIC 
41 Chloramphenicol, CHL = 8 2 16 1 MIC 
41 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
41 Clindamycin, CLN = 0.25 0.06 0.25 1 MIC 
41 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
41 Florfenicol, FFN = 4 2 8 1 MIC 
41 Gentamicin, GEN <= 1 0.12 1 1 MIC 
41 Linezolid, LZD = 2 1 4 1 MIC 
41 Mupirocin, MUP = 1 0 256 1 MIC 
41 Penicillin, PEN <= 0.12 0.25 2 0 MIC 
41 Quin.-Dalf. (Synercid), SYN = 1 0.25 1 1 MIC 
41 Tetracycline, TET = 0.5 0.12 1 1 MIC 
41 Trimethoprim, TMP = 2 1 4 1 MIC 
41 Vancomycin, VAN = 2 0.5 2 1 MIC 
42 Cefoxitin, FOX = 4 1 4 1 MIC 
42 Chloramphenicol, CHL = 8 2 16 1 MIC 
42 Ciprofloxacin, CIP <= 0.25 0.12 0.5 1 MIC 
42 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
42 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
42 Gentamicin, GEN <= 1 0.12 1 1 MIC 
42 Linezolid, LZD = 2 1 4 1 MIC 
42 Mupirocin, MUP <= 0.5 0 256 1 MIC 
42 Penicillin, PEN = 0.25 0.25 2 1 MIC 
42 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
42 Sulfisoxazole, FIS <= 64 32 128 1 MIC 
42 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
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42 Trimethoprim, TMP <= 2 1 4 1 MIC 
42 Vancomycin, VAN <= 1 0.5 2 1 MIC 
56 Cefoxitin, FOX = 4 1 4 1 MIC 
56 Chloramphenicol, CHL = 16 2 16 1 MIC 
56 Ciprofloxacin, CIP <= 0.25 0.12 0.5 1 MIC 
56 Clindamycin, CLN <= 0.12 0.06 0.25 1 MIC 
56 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
56 Gentamicin, GEN <= 1 0.12 1 1 MIC 
56 Linezolid, LZD = 4 1 4 1 MIC 
56 Mupirocin, MUP <= 0.5 0 256 1 MIC 
56 Penicillin, PEN = 0.5 0.25 2 1 MIC 
56 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
56 Sulfisoxazole, FIS = 128 32 128 1 MIC 
56 Tetracycline, TET = 1 0.12 1 1 MIC 
56 Trimethoprim, TMP <= 2 1 4 1 MIC 
56 Vancomycin, VAN <= 1 0.5 2 1 MIC 
58 Cefoxitin, FOX = 4 1 4 1 MIC 
58 Chloramphenicol, CHL = 8 2 16 1 MIC 
58 Ciprofloxacin, CIP = 0.5 0.12 0.5 1 MIC 
58 Clindamycin, CLN <= 0.125 0.06 0.25 1 MIC 
58 Erythromycin, ERY = 0.5 0.25 1 1 MIC 
58 Gentamicin, GEN <= 1 0.12 1 1 MIC 
58 Linezolid, LZD = 2 1 4 1 MIC 
58 Mupirocin, MUP <= 0.5 0 256 1 MIC 
58 Penicillin, PEN = 0.25 0.25 2 1 MIC 
58 Quin.-Dalf. (Synercid), SYN <= 0.5 0.25 1 1 MIC 
58 Tetracycline, TET <= 0.5 0.12 1 1 MIC 
58 Trimethoprim, TMP <= 2 1 4 1 MIC 
58 Vancomycin, VAN <= 1 0.5 2 1 MIC 
 
 
Appendix 6c, Page 1 of 10 
 
 
Appendix 6c- Test results from QC reference strain Escherichia coli ATCC 25922 
 
  
Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
1 Ampicillin, AMP = 4 2 8 1 MIC 
1 Cefotaxime, CTX <= 0.125 0.03 0.125 1 MIC 
1 Chloramphenicol, CHL = 4 2 8 1 MIC 
1 Ciprofloxacin, CIP <= 0.015 0.04 0.016 1 MIC 
1 Colistin, COL <= 1 0.25 2 1 MIC 
1 Florfenicol, FFN = 4 2 8 1 MIC 
1 Gentamicin, GEN <= 0.5 0.25 1 1 MIC 
1 Nalidixic acid, NAL <= 4 1 4 1 MIC 
1 Tetracycline, TET <= 2 0.5 2 1 MIC 
1 Trimethoprim, TMP <= 1 0.5 2 1 MIC 
2 Ampicillin, AMP = 4 2 8 1 MIC 
2 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
2 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
2 Chloramphenicol, CHL = 8 2 8 1 MIC 
2 Ciprofloxacin, CIP = 0.016 0.04 0.016 1 MIC 
2 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
2 Meropenem, MER = 0.03 0.008 0.06 1 MIC 
2 Nalidixic acid, NAL <= 2 1 4 1 MIC 
2 Tetracycline, TET = 2 0.5 2 1 MIC 
2 Trimethoprim, TMP = 1 0.5 2 1 MIC 
4 Ampicillin, AMP = 2 2 8 1 MIC 
4 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
4 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
4 Chloramphenicol, CHL = 8 2 8 1 MIC 
4 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
4 Colistin, COL = 2 0.25 2 1 MIC 
4 Florfenicol, FFN = 4 2 8 1 MIC 
4 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
4 Nalidixic acid, NAL = 4 1 4 1 MIC 
4 Sulfisoxazole, FIS = 16 8 32 1 MIC 
4 Tetracycline, TET = 1 0.5 2 1 MIC 
4 Trimethoprim, TMP = 1 0.5 2 1 MIC 
6 Ampicillin, AMP = 2 2 8 1 MIC 
6 Cefotaxime, CTX <  0.06 0.03 0.125 1 MIC 
6 Ceftazidime, CAZ <  0.25 0.06 0.5 1 MIC 
6 Chloramphenicol, CHL = 4 2 8 1 MIC 
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6 Ciprofloxacin, CIP <  0.008 0.04 0.016 1 MIC 
6 Florfenicol, FFN = 4 2 8 1 MIC 
6 Gentamicin, GEN = 0.25 0.25 1 1 MIC 
6 Nalidixic acid, NAL <  4 1 4 1 MIC 
6 Tetracycline, TET <  1 0.5 2 1 MIC 
6 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
9 Ampicillin, AMP = 4 2 8 1 MIC 
9 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
9 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
9 Chloramphenicol, CHL = 4 2 8 1 MIC 
9 Ciprofloxacin, CIP = 0.008 0.04 0.016 1 MIC 
9 Colistin, COL = 0.25 0.25 2 1 MIC 
9 Florfenicol, FFN = 4 2 8 1 MIC 
9 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
9 Meropenem, MER = 0.03 0.008 0.06 1 MIC 
9 Nalidixic acid, NAL = 4 1 4 1 MIC 
9 Sulfisoxazole, FIS = 16 8 32 1 MIC 
9 Tetracycline, TET = 1 0.5 2 1 MIC 
9 Trimethoprim, TMP = 1 0.5 2 1 MIC 
11 Ampicillin, AMP = 4 2 8 1 MIC 
11 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
11 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
11 Chloramphenicol, CHL <= 2 2 8 1 MIC 
11 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
11 Colistin, COL <= 0.5 0.25 2 1 MIC 
11 Florfenicol, FFN <= 4 2 8 1 MIC 
11 Gentamicin, GEN = 1 0.25 1 1 MIC 
11 Nalidixic acid, NAL = 2 1 4 1 MIC 
11 Sulfisoxazole, FIS = 16 8 32 1 MIC 
11 Tetracycline, TET <= 1 0.5 2 1 MIC 
11 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
12 Ampicillin, AMP = 2 2 8 1 MIC 
12 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
12 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC 
12 Chloramphenicol, CHL = 4 2 8 1 MIC 
12 Ciprofloxacin, CIP = 0.03 0.04 0.016 0 MIC 
12 Colistin, COL <= 0.5 0.25 2 1 MIC 
12 Florfenicol, FFN <= 4 2 8 1 MIC 
12 Gentamicin, GEN = 1 0.25 1 1 MIC 
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12 Nalidixic acid, NAL = 2 1 4 1 MIC 
12 Sulfisoxazole, FIS = 16 8 32 1 MIC 
12 Tetracycline, TET <= 1 0.5 2 1 MIC 
12 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
14 Ampicillin, AMP = 4 2 8 1 MIC 
14 Cefotaxime, CTX = 0.03 0.03 0.125 1 MIC 
14 Ciprofloxacin, CIP = 0.008 0.04 0.016 1 MIC 
14 Colistin, COL <= 0.5 0.25 2 1 MIC 
14 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
14 Meropenem, MER <= 0.12 0.008 0.06 1 MIC 
14 Nalidixic acid, NAL = 4 1 4 1 MIC 
14 Sulfisoxazole, FIS = 16 8 32 1 MIC 
14 Tetracycline, TET = 2 0.5 2 1 MIC 
14 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
15 Ceftazidime, CAZ = 32 25 32 1 DD 
15 Chloramphenicol, CHL = 25 21 27 1 DD 
15 Gentamicin, GEN = 26 19 26 1 DD 
15 Nalidixic acid, NAL = 25 22 28 1 DD 
15 Tetracycline, TET = 25 18 25 1 DD 
15 Trimethoprim, TMP = 26 21 28 1 DD 
16 Ampicillin, AMP = 4 2 8 1 MIC 
16 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
16 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
16 Chloramphenicol, CHL <= 4 2 8 1 MIC 
16 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
16 Colistin, COL <= 0.5 0.25 2 1 MIC 
16 Gentamicin, GEN <= 0.5 0.25 1 1 MIC 
16 Meropenem, MER <= 0.12 0.008 0.06 1 MIC 
16 Nalidixic acid, NAL <= 2 1 4 1 MIC 
16 Tetracycline, TET <= 1 0.5 2 1 MIC 
16 Trimethoprim, TMP = 1 0.5 2 1 MIC 
17 Ampicillin, AMP = 4 2 8 1 MIC 
17 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
17 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
17 Chloramphenicol, CHL = 4 2 8 1 MIC 
17 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
17 Colistin, COL <= 2 0.25 2 1 MIC 
17 Florfenicol, FFN = 4 2 8 1 MIC 
17 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
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17 Nalidixic acid, NAL <= 4 1 4 1 MIC 
17 Sulfisoxazole, FIS = 32 8 32 1 MIC 
17 Tetracycline, TET <= 1 0.5 2 1 MIC 
17 Trimethoprim, TMP = 1 0.5 2 1 MIC 
18 Ampicillin, AMP = 4 2 8 1 MIC 
18 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
18 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
18 Chloramphenicol, CHL = 4 2 8 1 MIC 
18 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
18 Colistin, COL <= 2 0.25 2 1 MIC 
18 Florfenicol, FFN = 4 2 8 1 MIC 
18 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
18 Nalidixic acid, NAL = 4 1 4 1 MIC 
18 Sulfisoxazole, FIS = 16 8 32 1 MIC 
18 Tetracycline, TET = 1 0.5 2 1 MIC 
18 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
19 Ampicillin, AMP = 4 2 8 1 MIC 
19 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
19 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
19 Chloramphenicol, CHL = 4 2 8 1 MIC 
19 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
19 Colistin, COL <= 2 0.25 2 1 MIC 
19 Florfenicol, FFN = 8 2 8 1 MIC 
19 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
19 Nalidixic acid, NAL <= 4 1 4 1 MIC 
19 Sulfisoxazole, FIS = 32 8 32 1 MIC 
19 Tetracycline, TET <= 1 0.5 2 1 MIC 
19 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
20 Ampicillin, AMP = 4 2 8 1 MIC 
20 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
20 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
20 Chloramphenicol, CHL = 4 2 8 1 MIC 
20 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
20 Colistin, COL <= 2 0.25 2 1 MIC 
20 Florfenicol, FFN = 4 2 8 1 MIC 
20 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
20 Meropenem, MER <= 1 0.008 0.06 1 MIC 
20 Nalidixic acid, NAL <= 4 1 4 1 MIC 
20 Sulfisoxazole, FIS = 32 8 32 1 MIC 
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20 Tetracycline, TET <= 1 0.5 2 1 MIC 
20 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
21 Ampicillin, AMP = 4 2 8 1 MIC 
21 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
21 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
21 Chloramphenicol, CHL = 4 2 8 1 MIC 
21 Ciprofloxacin, CIP = 0.008 0.04 0.016 1 MIC 
21 Colistin, COL = 2 0.25 2 1 MIC 
21 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
21 Nalidixic acid, NAL = 4 1 4 1 MIC 
21 Sulfisoxazole, FIS = 32 8 32 1 MIC 
21 Tetracycline, TET = 1 0.5 2 1 MIC 
21 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
22 Ampicillin, AMP = 4 2 8 1 MIC 
22 Cefotaxime, CTX <  0.06 0.03 0.125 1 MIC 
22 Ceftazidime, CAZ <  0.25 0.06 0.5 1 MIC 
22 Chloramphenicol, CHL = 4 2 8 1 MIC 
22 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
22 Florfenicol, FFN = 4 2 8 1 MIC 
22 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
22 Nalidixic acid, NAL <  4 1 4 1 MIC 
22 Sulfisoxazole, FIS = 16 8 32 1 MIC 
22 Tetracycline, TET = 1 0.5 2 1 MIC 
22 Trimethoprim, TMP = 1 0.5 2 1 MIC 
23 Ampicillin, AMP = 2 2 8 1 MIC 
23 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
23 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
23 Chloramphenicol, CHL = 4 2 8 1 MIC 
23 Ciprofloxacin, CIP = 0.008 0.04 0.016 1 MIC 
23 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
23 Nalidixic acid, NAL = 4 1 4 1 MIC 
23 Sulfisoxazole, FIS = 32 8 32 1 MIC 
23 Tetracycline, TET = 1 0.5 2 1 MIC 
23 Trimethoprim, TMP = 1 0.5 2 1 MIC 
25 Ampicillin, AMP = 8 2 8 1 MIC 
25 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
25 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC 
25 Chloramphenicol, CHL = 8 2 8 1 MIC 
25 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
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25 Colistin, COL <= 2 0.25 2 1 MIC 
25 Florfenicol, FFN = 8 2 8 1 MIC 
25 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
25 Nalidixic acid, NAL <= 4 1 4 1 MIC 
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC 
25 Tetracycline, TET <= 1 0.5 2 1 MIC 
25 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
26 Ampicillin, AMP = 4 2 8 1 MIC 
26 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
26 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
26 Chloramphenicol, CHL = 4 2 8 1 MIC 
26 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
26 Colistin, COL <= 2 0.25 2 1 MIC 
26 Florfenicol, FFN <= 2 2 8 1 MIC 
26 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
26 Nalidixic acid, NAL <= 4 1 4 1 MIC 
26 Tetracycline, TET <= 1 0.5 2 1 MIC 
26 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
29 Ampicillin, AMP = 4 2 8 1 MIC 
29 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
29 Ceftazidime, CAZ = 0.06 0.06 0.5 1 MIC 
29 Chloramphenicol, CHL = 2 2 8 1 MIC 
29 Ciprofloxacin, CIP = 0.016 0.04 0.016 1 MIC 
29 Florfenicol, FFN = 8 2 8 1 MIC 
29 Gentamicin, GEN = 1 0.25 1 1 MIC 
29 Nalidixic acid, NAL = 2 1 4 1 MIC 
29 Tetracycline, TET = 1 0.5 2 1 MIC 
29 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
30 Ampicillin, AMP = 2 2 8 1 MIC 
30 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
30 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
30 Chloramphenicol, CHL = 4 2 8 1 MIC 
30 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
30 Colistin, COL <= 2 0.25 2 1 MIC 
30 Florfenicol, FFN <= 2 2 8 1 MIC 
30 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
30 Meropenem, MER <= 1 0.008 0.06 1 MIC 
30 Nalidixic acid, NAL <= 4 1 4 1 MIC 
30 Sulfisoxazole, FIS = 16 8 32 1 MIC 
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30 Tetracycline, TET <= 1 0.5 2 1 MIC 
30 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
32 Ampicillin, AMP = 2 2 8 1 MIC 
32 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
32 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
32 Chloramphenicol, CHL = 4 2 8 1 MIC 
32 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
32 Colistin, COL <= 2 0.25 2 1 MIC 
32 Florfenicol, FFN = 4 2 8 1 MIC 
32 Gentamicin, GEN = 1 0.25 1 1 MIC 
32 Nalidixic acid, NAL <= 4 1 4 1 MIC 
32 Sulfisoxazole, FIS = 32 8 32 1 MIC 
32 Tetracycline, TET <= 1 0.5 2 1 MIC 
32 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
33 Ampicillin, AMP = 4 2 8 1 MIC 
33 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
33 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC 
33 Chloramphenicol, CHL = 4 2 8 1 MIC 
33 Ciprofloxacin, CIP = 0.03 0.04 0.016 0 MIC 
33 Colistin, COL = 1 0.25 2 1 MIC 
33 Florfenicol, FFN <= 4 2 8 1 MIC 
33 Gentamicin, GEN = 1 0.25 1 1 MIC 
33 Nalidixic acid, NAL = 2 1 4 1 MIC 
33 Sulfisoxazole, FIS = 32 8 32 1 MIC 
33 Tetracycline, TET <= 1 0.5 2 1 MIC 
33 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
34 Ampicillin, AMP = 4 2 8 1 MIC 
34 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
34 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
34 Chloramphenicol, CHL = 4 2 8 1 MIC 
34 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 MIC 
34 Colistin, COL <= 2 0.25 2 1 MIC 
34 Florfenicol, FFN = 4 2 8 1 MIC 
34 Gentamicin, GEN = 1 0.25 1 1 MIC 
34 Nalidixic acid, NAL <= 4 1 4 1 MIC 
34 Sulfisoxazole, FIS = 16 8 32 1 MIC 
34 Tetracycline, TET <= 1 0.5 2 1 MIC 
34 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
36 Ampicillin, AMP = 4 2 8 1 MIC 
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36 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
36 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC 
36 Chloramphenicol, CHL = 4 2 8 1 MIC 
36 Ciprofloxacin, CIP = 0.03 0.04 0.016 0 MIC 
36 Colistin, COL <= 0.5 0.25 2 1 MIC 
36 Florfenicol, FFN <= 4 2 8 1 MIC 
36 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
36 Nalidixic acid, NAL = 2 1 4 1 MIC 
36 Sulfisoxazole, FIS = 32 8 32 1 MIC 
36 Tetracycline, TET <= 1 0.5 2 1 MIC 
36 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
37 Ampicillin, AMP = 4 2 8 1 AGA 
37 Cefotaxime, CTX <= 0.06 0.03 0.125 1 AGA 
37 Ceftazidime, CAZ = 0.25 0.06 0.5 1 AGA 
37 Chloramphenicol, CHL = 4 2 8 1 AGA 
37 Ciprofloxacin, CIP <= 0.008 0.04 0.016 1 AGA 
37 Gentamicin, GEN = 0.5 0.25 1 1 AGA 
37 Nalidixic acid, NAL <= 2 1 4 1 AGA 
37 Tetracycline, TET = 1 0.5 2 1 AGA 
37 Trimethoprim, TMP = 0.5 0.5 2 1 AGA 
39 Ampicillin, AMP = 2 2 8 1 MIC 
39 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
39 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC 
39 Chloramphenicol, CHL = 8 2 8 1 MIC 
39 Ciprofloxacin, CIP = 0.16 0.04 0.016 0 MIC 
39 Colistin, COL <= 0.5 0.25 2 1 MIC 
39 Florfenicol, FFN = 8 2 8 1 MIC 
39 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
39 Nalidixic acid, NAL = 2 1 4 1 MIC 
39 Tetracycline, TET <= 1 0.5 2 1 MIC 
39 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
40 Ampicillin, AMP = 21 16 22 1 DD 
40 Cefotaxime, CTX = 32 29 35 1 DD 
40 Ceftazidime, CAZ = 28 25 32 1 DD 
40 Chloramphenicol, CHL = 24 21 27 1 DD 
40 Ciprofloxacin, CIP = 34 30 40 1 DD 
40 Gentamicin, GEN = 22 19 26 1 DD 
40 Meropenem, MER = 30 28 34 1 DD 
40 Nalidixic acid, NAL = 27 22 28 1 DD 
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Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
40 Sulfisoxazole, FIS = 21 15 23 1 DD 
40 Tetracycline, TET = 22 18 25 1 DD 
40 Trimethoprim, TMP = 27 21 28 1 DD 
41 Ampicillin, AMP = 4 2 8 1 MIC 
41 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC 
41 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC 
41 Chloramphenicol, CHL = 8 2 8 1 MIC 
41 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
41 Colistin, COL = 2 0.25 2 1 MIC 
41 Florfenicol, FFN = 4 2 8 1 MIC 
41 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
41 Nalidixic acid, NAL = 4 1 4 1 MIC 
41 Tetracycline, TET = 1 0.5 2 1 MIC 
41 Trimethoprim, TMP = 0.5 0.5 2 1 MIC 
42 Ampicillin, AMP = 8 2 8 1 MIC 
42 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC 
42 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
42 Chloramphenicol, CHL = 4 2 8 1 MIC 
42 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
42 Colistin, COL <= 2 0.25 2 1 MIC 
42 Florfenicol, FFN = 8 2 8 1 MIC 
42 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
42 Meropenem, MER <= 1 0.008 0.06 1 MIC 
42 Nalidixic acid, NAL <= 4 1 4 1 MIC 
42 Sulfisoxazole, FIS = 32 8 32 1 MIC 
42 Tetracycline, TET = 2 0.5 2 1 MIC 
42 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
45 Ampicillin, AMP = 0 16 22 0 DD 
45 Cefotaxime, CTX = 32.1 29 35 1 DD 
45 Ceftazidime, CAZ = 29.2 25 32 1 DD 
45 Chloramphenicol, CHL = 22.9 21 27 1 DD 
45 Ciprofloxacin, CIP = 34.0 30 40 1 DD 
45 Colistin, COL = 15.4 11 17 1 DD 
45 Gentamicin, GEN = 19.3 19 26 1 DD 
45 Meropenem, MER = 31.5 28 34 1 DD 
45 Nalidixic acid, NAL = 26.9 22 28 1 DD 
45 Sulfisoxazole, FIS = 19 15 23 1 DD 
45 Tetracycline, TET = 23.1 18 25 1 DD 
45 Trimethoprim, TMP = 25.8 21 28 1 DD 
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Lab no Antib Operator Value Low limit High 
limit 
Mark Method 
56 Ampicillin, AMP = 4 2 8 1 MIC 
56 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC 
56 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
56 Chloramphenicol, CHL = 4 2 8 1 MIC 
56 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
56 Colistin, COL <= 2 0.25 2 1 MIC 
56 Florfenicol, FFN = 4 2 8 1 MIC 
56 Gentamicin, GEN <= 0.25 0.25 1 1 MIC 
56 Nalidixic acid, NAL <= 4 1 4 1 MIC 
56 Sulfisoxazole, FIS = 32 8 32 1 MIC 
56 Tetracycline, TET <= 1 0.5 2 1 MIC 
56 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
58 Ampicillin, AMP = 8 2 8 1 MIC 
58 Cefotaxime, CTX = 0.125 0.03 0.125 1 MIC 
58 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC 
58 Chloramphenicol, CHL = 8 2 8 1 MIC 
58 Ciprofloxacin, CIP = 0.015 0.04 0.016 1 MIC 
58 Colistin, COL <= 2 0.25 2 1 MIC 
58 Florfenicol, FFN = 8 2 8 1 MIC 
58 Gentamicin, GEN = 0.5 0.25 1 1 MIC 
58 Meropenem, MER = 0.016 0.008 0.06 1 MIC 
58 Nalidixic acid, NAL <= 4 1 4 1 MIC 
58 Sulfisoxazole, FIS = 32 8 32 1 MIC 
58 Tetracycline, TET <= 1 0.5 2 1 MIC 
58 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC 
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Appendix 7a- Summary of results Enterococci trial 
 
Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Ampicillin , AMP 
  
  
  
  
  
EURL ENT 7.1 S 0 100 24 0 
EURL ENT 7.2 * 61 39 *  
EURL ENT 7.3 * 71 29 *  
EURL ENT 7.4 S 0 100 24 0 
EURL ENT 7.5 S 4 96 23 1 
EURL ENT 7.6 S 0 100 24 0 
EURL ENT 7.7 S 17 83 20 4 
EURL ENT 7.8 R 100 0 24 0 
Chloramphenicol, CHL 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 29 0 
EURL ENT 7.2 S 0 100 29 0 
EURL ENT 7.3 S 0 100 29 0 
EURL ENT 7.4 S 0 100 29 0 
EURL ENT 7.5 S 0 100 29 0 
EURL ENT 7.6 R 100 0 28 0 
EURL ENT 7.7 S 0 100 29 0 
EURL ENT 7.8 S 0 100 29 0 
Ciprofloxacin , CIP 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 24 0 
EURL ENT 7.2 S 0 100 24 0 
EURL ENT 7.3 S 0 100 24 0 
EURL ENT 7.4 R 96 4 22 1 
EURL ENT 7.5 S 0 100 24 0 
EURL ENT 7.6 S 4 96 23 1 
EURL ENT 7.7 S 0 100 24 0 
EURL ENT 7.8 R 100 0 23 0 
Daptomycin, DAP 
  
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 11 0 
EURL ENT 7.2 S 18 82 9 2 
EURL ENT 7.3 S 0 100 11 0 
EURL ENT 7.4 S 0 100 11 0 
EURL ENT 7.5 S 0 100 11 0 
EURL ENT 7.6 S 0 100 11 0 
EURL ENT 7.7 S 0 100 11 0 
EURL ENT 7.8 S 27 73 8 3 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Erythromycin, ERY 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 29 0 
EURL ENT 7.2 R 93 7 27 2 
EURL ENT 7.3 R 100 0 29 0 
EURL ENT 7.4 S 3 97 28 1 
EURL ENT 7.5 R 97 3 28 1 
EURL ENT 7.6 R 100 0 29 0 
EURL ENT 7.7 S 3 97 28 1 
EURL ENT 7.8 R 100 0 29 0 
Gentamicin, GEN 
  
  
  
  
  
  
  
EURL ENT 7.1 S 8 92 22 2 
EURL ENT 7.2 S 4 96 23 1 
EURL ENT 7.3 S 4 96 23 1 
EURL ENT 7.4 S 4 96 23 1 
EURL ENT 7.5 R 96 4 27 1 
EURL ENT 7.6 R 100 0 27 0 
EURL ENT 7.7 S 8 92 22 2 
EURL ENT 7.8 R 100 0 28 0 
Linezolid, LZD 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 27 0 
EURL ENT 7.2 S 0 100 27 0 
EURL ENT 7.3 S 0 100 27 0 
EURL ENT 7.4 S 0 100 27 0 
EURL ENT 7.5 S 0 100 27 0 
EURL ENT 7.6 S 0 100 27 0 
EURL ENT 7.7 S 0 100 27 0 
EURL ENT 7.8 S 0 100 27 0 
Quin.-Dalf. (Synercid), SYN 
  
  
EURL ENT 7.2 * 25 75 *  
EURL ENT 7.3 * 71 29 *  
EURL ENT 7.4 S 0 100 18 0 
EURL ENT 7.7 S 0 100 17 0 
EURL ENT 7.8 S 0 100 18 0 
Teicoplanin, TEI 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 5 0 
EURL ENT 7.2 S 0 100 6 0 
EURL ENT 7.3 R 100 0 5 0 
EURL ENT 7.4 S 0 100 5 0 
EURL ENT 7.5 S 0 100 6 0 
EURL ENT 7.6 S 0 100 6 0 
EURL ENT 7.7 R 100 0 5 0 
EURL ENT 7.8 S 0 100 6 0 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Tetracycline, TET 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 29 0 
EURL ENT 7.2 S 0 100 29 0 
EURL ENT 7.3 R 97 3 28 1 
EURL ENT 7.4 S 0 100 29 0 
EURL ENT 7.5 R 100 0 29 0 
EURL ENT 7.6 R 100 0 29 0 
EURL ENT 7.7 R 100 0 29 0 
EURL ENT 7.8 S 0 100 29 0 
Tigecycline, TGC 
  
  
  
  
EURL ENT 7.2 S 0 100 12 0 
EURL ENT 7.3 S 0 100 13 0 
EURL ENT 7.4 S 0 100 13 0 
EURL ENT 7.7 S 0 100 13 0 
EURL ENT 7.8 S 0 100 13 0 
Vancomycin, VAN 
  
  
  
  
  
  
  
EURL ENT 7.1 S 0 100 29 0 
EURL ENT 7.2 S 0 100 29 0 
EURL ENT 7.3 R 100 0 29 0 
EURL ENT 7.4 S 0 100 29 0 
EURL ENT 7.5 S 3 97 28 1 
EURL ENT 7.6 S 3 97 28 1 
EURL ENT 7.7 R 100 0 29 0 
EURL ENT 7.8 S 0 100 29 0 
• Combinations subtracted before evaluation due to breakpoint issues leading 
to deviation level of 25 or above. 
 Combination ENT 7.8/daptomycin subtracted from report as it caused 
more than 25% deviation. 
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Appendix 7b- Summary of results Staphylococci trial 
Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Cefoxitin, FOX 
  
  
  
  
  
  
  
EURL ST 7.1 R 97 3 29 1 
EURL ST 7.2 S 3 97 29 1 
EURL ST 7.3 R 97 3 29 1 
EURL ST 7.4 R 100 0 30 0 
EURL ST 7.5 R 100 0 30 0 
EURL ST 7.6 S 3 97 28 1 
EURL ST 7.7 R 100 0 30 0 
EURL ST 7.8 R 100 0 30 0 
Chloramphenicol, CHL 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 32 0 
EURL ST 7.2 S 0 100 32 0 
EURL ST 7.3 S 0 100 32 0 
EURL ST 7.4 S 0 100 32 0 
EURL ST 7.5 S 3 97 31 1 
EURL ST 7.6 S 0 100 32 0 
EURL ST 7.7 S 0 100 32 0 
EURL ST 7.8 S 0 100 32 0 
Ciprofloxacin, CIP 
  
  
  
  
  
  
EURL ST 7.1 S 3 97 32 1 
EURL ST 7.2 S 3 97 32 1 
EURL ST 7.3 S 0 100 33 0 
EURL ST 7.5 S 0 100 33 0 
EURL ST 7.6 S 3 97 32 1 
EURL ST 7.7 S 0 100 33 0 
EURL ST 7.8 S 0 100 33 0 
Clindamycin, CLN 
  
  
  
  
  
  
  
EURL ST 7.1 S 18 82 23 5 
EURL ST 7.2 S 7 93 26 2 
EURL ST 7.3 R 100 0 28 0 
EURL ST 7.4 S 14 86 24 4 
EURL ST 7.5 S 11 89 25 3 
EURL ST 7.6 R 96 4 27 1 
EURL ST 7.7 R 100 0 28 0 
EURL ST 7.8 S 11 89 24 3 
Erythromycin, ERY 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 34 0 
EURL ST 7.2 S 0 100 34 0 
EURL ST 7.3 S 0 100 34 0 
EURL ST 7.4 S 3 97 33 1 
EURL ST 7.5 S 0 100 34 0 
EURL ST 7.6 R 97 3 33 1 
EURL ST 7.7 S 6 94 32 2 
EURL ST 7.8 S 0 100 34 0 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Florfenicol, FFN 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 11 0 
EURL ST 7.2 S 0 100 10 0 
EURL ST 7.3 S 0 100 10 0 
EURL ST 7.4 S 0 100 10 0 
EURL ST 7.5 S 0 100 10 0 
EURL ST 7.6 S 0 100 10 0 
EURL ST 7.7 S 0 100 10 0 
EURL ST 7.8 S 0 100 10 0 
Gentamicin, GEN 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 32 0 
EURL ST 7.2 S 0 100 33 0 
EURL ST 7.3 S 0 100 33 0 
EURL ST 7.4 R 100 0 33 0 
EURL ST 7.5 S 3 97 32 1 
EURL ST 7.6 R 97 3 32 1 
EURL ST 7.7 S 3 97 32 1 
EURL ST 7.8 S 0 100 33 0 
Linezolid, LZD 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 23 0 
EURL ST 7.2 S 0 100 21 0 
EURL ST 7.3 S 0 100 23 0 
EURL ST 7.4 S 0 100 23 0 
EURL ST 7.5 S 0 100 23 0 
EURL ST 7.6 S 0 100 23 0 
EURL ST 7.7 S 0 100 23 0 
EURL ST 7.8 S 0 100 23 0 
Mupirocin, MUP 
  
  
  
  
  
  
  
EURL ST 7.1 S 6 94 17 1 
EURL ST 7.2 S 0 100 18 0 
EURL ST 7.3 S 0 100 18 0 
EURL ST 7.4 S 0 100 18 0 
EURL ST 7.5 S 0 100 18 0 
EURL ST 7.6 S 0 100 17 0 
EURL ST 7.7 S 0 100 18 0 
EURL ST 7.8 S 0 100 18 0 
Penicillin, PEN 
  
  
  
  
  
  
  
EURL ST 7.1 R 97 3 32 1 
EURL ST 7.2 R 100 0 33 0 
EURL ST 7.3 R 100 0 33 0 
EURL ST 7.4 R 100 0 33 0 
EURL ST 7.5 R 100 0 33 0 
EURL ST 7.6 R 100 0 33 0 
EURL ST 7.7 R 100 0 33 0 
EURL ST 7.8 R 97 3 32 1 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Quin.-Dalf. (Synercid), SYN 
  
  
  
  
  
  
EURL ST 7.1 S 5 95 21 1 
EURL ST 7.2 S 0 100 22 0 
EURL ST 7.3 R 80 20 16 4 
EURL ST 7.4 S 5 95 21 1 
EURL ST 7.5 S 9 91 20 2 
EURL ST 7.7 R 80 20 16 4 
EURL ST 7.8 S 0 100 21 0 
Sulfamethoxazole, SMX 
  
  
  
  
  
  
  
EURL ST 7.1 S 4 96 25 1 
EURL ST 7.2 S 15 85 22 4 
EURL ST 7.3 S 0 100 26 0 
EURL ST 7.4 R 84 16 21 4 
EURL ST 7.5 S 0 100 26 0 
EURL ST 7.6 S 4 96 25 1 
EURL ST 7.7 S 0 100 26 0 
EURL ST 7.8 S 0 100 25 0 
Tetracycline, TET 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 34 0 
EURL ST 7.2 S 3 97 33 1 
EURL ST 7.3 R 100 0 34 0 
EURL ST 7.4 R 100 0 34 0 
EURL ST 7.5 R 100 0 34 0 
EURL ST 7.6 R 100 0 34 0 
EURL ST 7.7 R 100 0 34 0 
EURL ST 7.8 R 100 0 34 0 
Trimethoprim, TMP 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 32 0 
EURL ST 7.2 S 22 78 25 7 
EURL ST 7.3 R 100 0 32 0 
EURL ST 7.4 S 3 97 31 1 
EURL ST 7.5 S 3 97 31 1 
EURL ST 7.6 R 97 3 31 1 
EURL ST 7.7 R 100 0 32 0 
EURL ST 7.8 S 3 97 31 1 
Vancomycin, VAN 
  
  
  
  
  
  
  
EURL ST 7.1 S 0 100 22 0 
EURL ST 7.2 S 0 100 22 0 
EURL ST 7.3 S 0 100 22 0 
EURL ST 7.4 S 0 100 22 0 
EURL ST 7.5 S 0 100 22 0 
EURL ST 7.6 S 0 100 22 0 
EURL ST 7.7 S 0 100 22 0 
EURL ST 7.8 S 0 100 22 0 
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Appendix 7c- Summary of results E.coli trial 
 
Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Ampicillin, AMP 
  
  
  
  
  
  
  
EURL EC 7.1 R 100 0 34 0 
EURL EC 7.2 R 100 0 34 0 
EURL EC 7.3 R 100 0 34 0 
EURL EC 7.4 R 100 0 34 0 
EURL EC 7.5 S 6 94 32 2 
EURL EC 7.6 R 100 0 34 0 
EURL EC 7.7 R 100 0 34 0 
EURL EC 7.8 R 100 0 34 0 
Cefotaxime, CTX 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 34 0 
EURL EC 7.2 R 100 0 34 0 
EURL EC 7.3 R 100 0 34 0 
EURL EC 7.4 R 100 0 34 0 
EURL EC 7.5 S 0 100 34 0 
EURL EC 7.6 S 0 100 34 0 
EURL EC 7.7 S 0 100 34 0 
EURL EC 7.8 R 100 0 34 0 
Ceftazidime, CAZ 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 32 0 
EURL EC 7.2 R 88 13 28 4 
EURL EC 7.3 R 100 0 33 0 
EURL EC 7.4 R 94 6 30 2 
EURL EC 7.5 S 0 100 32 0 
EURL EC 7.6 S 0 100 32 0 
EURL EC 7.7 S 3 97 31 1 
EURL EC 7.8 R 100 0 33 0 
Chloramphenicol, CHL 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 33 0 
EURL EC 7.2 S 0 100 33 0 
EURL EC 7.3 S 0 100 33 0 
EURL EC 7.4 S 0 100 33 0 
EURL EC 7.5 S 0 100 33 0 
EURL EC 7.6 R 97 3 32 1 
EURL EC 7.7 R 100 0 33 0 
EURL EC 7.8 S 0 100 33 0 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Ciprofloxacin, CIP 
  
  
  
  
  
  
  
EURL EC 7.1 R 94 6 31 2 
EURL EC 7.2 S 0 100 34 0 
EURL EC 7.3 S 0 100 34 0 
EURL EC 7.4 S 0 100 34 0 
EURL EC 7.5 S 0 100 34 0 
EURL EC 7.6 S 0 100 34 0 
EURL EC 7.7 S 0 100 34 0 
EURL EC 7.8 R 91 9 31 3 
Colistin, COL 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 29 0 
EURL EC 7.2 S 3 97 28 1 
EURL EC 7.3 S 0 100 29 0 
EURL EC 7.4 S 0 100 29 0 
EURL EC 7.5 S 0 100 29 0 
EURL EC 7.6 S 0 100 29 0 
EURL EC 7.7 S 0 100 29 0 
EURL EC 7.8 S 0 100 29 0 
Florfenicol, FFN 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 28 0 
EURL EC 7.2 S 0 100 28 0 
EURL EC 7.3 S 0 100 28 0 
EURL EC 7.4 S 0 100 28 0 
EURL EC 7.5 S 0 100 28 0 
EURL EC 7.6 S 7 93 26 2 
EURL EC 7.7 R 100 0 28 0 
EURL EC 7.8 S 0 100 28 0 
Gentamicin, GEN 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 34 0 
EURL EC 7.2 S 0 100 34 0 
EURL EC 7.3 S 0 100 34 0 
EURL EC 7.4 S 0 100 34 0 
EURL EC 7.5 S 0 100 34 0 
EURL EC 7.6 S 0 100 34 0 
EURL EC 7.7 R 97 3 33 1 
EURL EC 7.8 S 0 100 34 0 
Meropenem, MER 
  
  
  
  
  
  
  
EURL EC 7.1 S 0 100 12 0 
EURL EC 7.2 S 0 100 13 0 
EURL EC 7.3 S 0 100 13 0 
EURL EC 7.4 S 0 100 13 0 
EURL EC 7.5 S 0 100 12 0 
EURL EC 7.6 S 0 100 12 0 
EURL EC 7.7 S 0 100 12 0 
EURL EC 7.8 S 0 100 13 0 
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Antimicrobial Strain Expected result % R % S 
Number 
expected 
results 
Number 
deviating 
results 
Nalidixic acid, NAL 
  
  
  
  
  
  
  
EURL EC 7.1 R 100 0 34 0 
EURL EC 7.2 S 0 100 34 0 
EURL EC 7.3 S 0 100 34 0 
EURL EC 7.4 S 0 100 34 0 
EURL EC 7.5 S 3 97 33 1 
EURL EC 7.6 S 3 97 33 1 
EURL EC 7.7 S 0 100 34 0 
EURL EC 7.8 R 100 0 34 0 
Sulfamethoxazole, SMX 
  
  
  
  
  
  
  
EURL EC 7.1 R 100 0 33 0 
EURL EC 7.2 R 100 0 33 0 
EURL EC 7.3 S 6 94 31 2 
EURL EC 7.4 S 0 100 33 0 
EURL EC 7.5 S 6 94 31 2 
EURL EC 7.6 S 3 97 31 1 
EURL EC 7.7 R 100 0 33 0 
EURL EC 7.8 S 6 94 31 2 
Tetracycline, TET 
  
  
  
  
  
  
  
EURL EC 7.1 R 100 0 34 0 
EURL EC 7.2 R 100 0 34 0 
EURL EC 7.3 S 0 100 34 0 
EURL EC 7.4 S 0 100 34 0 
EURL EC 7.5 S 0 100 34 0 
EURL EC 7.6 R 100 0 34 0 
EURL EC 7.7 S 0 100 33 0 
EURL EC 7.8 S 0 100 34 0 
Trimethoprim, TMP 
  
  
  
  
  
  
  
EURL EC 7.1 R 100 0 34 0 
EURL EC 7.2 R 100 0 34 0 
EURL EC 7.3 S 0 100 34 0 
EURL EC 7.4 S 0 100 34 0 
EURL EC 7.5 S 0 100 34 0 
EURL EC 7.6 S 3 97 33 1 
EURL EC 7.7 R 100 0 34 0 
EURL EC 7.8 S 0 100 34 0 
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Appendix 8a- Deviations of results Enterococci trial 
Lab no. Strain Antimicrobial Obtained interpretation 
Obtained 
value 
Expected 
interpretation 
Expected 
Mic 
LAB. 006 
  
  
EURL ENT 7.6 Ciprofloxacin , CIP R >4 S 1 
EURL ENT 7.6 Vancomycin, VAN R >32 S 1 
EURL ENT 7.8 Daptomycin, DAP R 8 S 4 
LAB. 011 
  
  
  
EURL ENT 7.5 Ampicillin , AMP R 8 S <=2 
EURL ENT 7.5 Erythromycin, ERY S 2 R >32 
EURL ENT 7.5 Gentamicin, GEN S 8 R >1024 
EURL ENT 7.5 Vancomycin, VAN R >128 S 1 
LAB. 012 
  
EURL ENT 7.4 Erythromycin, ERY R 8 S 2 
LAB. 020 
  
EURL ENT 7.7 Ampicillin , AMP R 8 S 4 
LAB. 022 
  
EURL ENT 7.7 Ampicillin , AMP R =8 S 4 
LAB. 025 EURL ENT 7.7 Ampicillin , AMP R 8 S 4 
LAB. 026 
  
  
  
  
EURL ENT 7.1 Gentamicin, GEN R 128 S <=16 
EURL ENT 7.2 Gentamicin, GEN R 128 S <=16 
EURL ENT 7.3 Gentamicin, GEN R 128 S <=16 
EURL ENT 7.4 Gentamicin, GEN R 128 S <=16 
EURL ENT 7.7 Gentamicin, GEN R 128 S <=16 
LAB. 029 EURL ENT 7.4 Ciprofloxacin , CIP S 16mm R 8 
LAB. 032 
  
EURL ENT 7.2 Daptomycin, DAP R <=8 S 4 
EURL ENT 7.8 Daptomycin, DAP R <=8 S 4 
LAB. 039 
  
EURL ENT 7.2 Erythromycin, ERY S 4 R >32 
EURL ENT 7.7 Ampicillin , AMP R 8 S 4 
LAB. 040 EURL ENT 7.2 Erythromycin, ERY S 14 R >32 
LAB. 041 
  
  
  
EURL ENT 7.2 Daptomycin, DAP R >4 S 4 
EURL ENT 7.7 Erythromycin, ERY R >4 S 1 
EURL ENT 7.7 Gentamicin, GEN R >16 S <=16 
EURL ENT 7.8 Daptomycin, DAP R >4 S 4 
LAB. 045 EURL ENT 7.1 Gentamicin, GEN R 11.1 S <=16 
LAB. 046 EURL ENT 7.3 Tetracycline, TET S >8 R >32 
 
 Combination ENT 7.8/daptomycin subtracted from report as it caused more 
than 25% deviation. 
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Appendix 8b- Deviations to results Staphylococci trial 
 
Lab no. Antimicrobial Obtained interpretation 
Obtained 
value 
Expected 
interpretation 
Expected 
Mic 
LAB. 002 Sulfamethoxazole, SMX R 512 S <=32 
LAB. 004 Tetracycline, TET R 25.77 S <=0.5 
  Trimethoprim, TMP R 18.45 S 2 
LAB. 006 Penicillin, PEN S 2 R 0.5 
  Cefoxitin, FOX R 16 S 4 
  Clindamycin, CLN R >4 S 0.12 
  Erythromycin, ERY R >8 S <=0.25 
  Quin.-Dalf. (Synercid), SYN R 2 S 0.5 
  Trimethoprim, TMP R >32 S <=0.5 
  Clindamycin, CLN R >4 S 0.12 
  Gentamicin, GEN R 16 S 0.25 
  Quin.-Dalf. (Synercid), SYN R 2 S 0.5 
  Trimethoprim, TMP R >32 S <=1 
  Sulfamethoxazole, SMX R 256 S <=32 
  Quin.-Dalf. (Synercid), SYN S 1 R 2 
LAB. 011 Erythromycin, ERY R >32 S 0.5 
  Gentamicin, GEN R 64 S <=0.25 
LAB. 012 Trimethoprim, TMP R 4 S 2 
LAB. 015 Quin.-Dalf. (Synercid), SYN S   R 2 
  Quin.-Dalf. (Synercid), SYN S   R 2 
LAB. 017 Trimethoprim, TMP R 4 S 2 
  Clindamycin, CLN R 0.5 S 0.12 
LAB. 018 Quin.-Dalf. (Synercid), SYN S 20 R 2 
  Quin.-Dalf. (Synercid), SYN R 24 S 0.5 
  Quin.-Dalf. (Synercid), SYN S 19 R 2 
  Trimethoprim, TMP R 6 S 1 
LAB. 021 Penicillin, PEN S 2 R 8 
LAB. 022 Clindamycin, CLN R =0.5 S 0.12 
  Trimethoprim, TMP R =4 S 2 
LAB. 026 Clindamycin, CLN R 1 S 0.12 
  Mupirocin, MUP R 2 S 0.06 
  Quin.-Dalf. (Synercid), SYN R 2 S 0.5 
  Quin.-Dalf. (Synercid), SYN S 1 R 2 
LAB. 029 Sulfamethoxazole, SMX S 27mm R 256 
LAB. 030 Cefoxitin, FOX R 16 S 4 
  Clindamycin, CLN S <= 0.12 R >256 
  Erythromycin, ERY S <= 0.25 R >16 
  Gentamicin, GEN S <= 1 R >16 
  Trimethoprim, TMP S <= 2 R >32 
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Lab no. Antimicrobial Obtained interpretation 
Obtained 
value 
Expected 
interpretation 
Expected 
Mic 
LAB. 033 Clindamycin, CLN R 0.5 S 0.12 
  Trimethoprim, TMP R 4 S 2 
LAB. 034 Trimethoprim, TMP R 4 S 2 
  Sulfamethoxazole, SMX S <=64 R 256 
LAB. 036 Clindamycin, CLN R 1 S 0.12 
  Clindamycin, CLN R 1 S 0.12 
  Trimethoprim, TMP R 4 S 2 
  Clindamycin, CLN R 0.5 S 0.12 
  Clindamycin, CLN R 0.5 S 0.12 
LAB. 037 Sulfamethoxazole, SMX S 128 R 256 
LAB. 039 Ciprofloxacin, CIP R 2 S 0.25 
  Clindamycin, CLN R 2 S 0.12 
  Ciprofloxacin, CIP R 2 S 0.5 
  Clindamycin, CLN R 2 S 0.12 
  Clindamycin, CLN R 2 S 0.12 
  Clindamycin, CLN R 2 S 0.12 
  Ciprofloxacin, CIP R >4 S 0.5 
  Erythromycin, ERY R 2 S 0.5 
  Clindamycin, CLN R 2 S 0.12 
LAB. 040 Quin.-Dalf. (Synercid), SYN S 22 R 2 
  Sulfamethoxazole, SMX S 19 R 256 
  Quin.-Dalf. (Synercid), SYN S 20 R 2 
LAB. 041 Sulfamethoxazole, SMX R 256 S <=32 
  Clindamycin, CLN R 1 S 0.12 
LAB. 042 Sulfamethoxazole, SMX R >512 S <=32 
LAB. 045 Clindamycin, CLN R 0 S 0.12 
  Chloramphenicol, CHL R 10.6 S 8 
LAB. 046 Cefoxitin, FOX S 4 R 8 
  Cefoxitin, FOX S 4 R 16 
LAB. 056 Sulfamethoxazole, SMX R >512 S <=32 
  Sulfamethoxazole, SMX R >512 S <=32 
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Appendix 8c- Deviations to results E.coli trial 
 
Lab no. Strain Antimicrobial Obtained interpretation 
Obtained 
value 
Expected 
interpretation 
Expected 
Mic 
LAB. 004 EURL EC 7.5 Sulfamethoxazole, SMX R 1024 S <=16 
LAB. 006 EURL EC 7.8 Sulfamethoxazole, SMX R <=8 S <=16 
LAB. 011 EURL EC 7.6 Chloramphenicol, CHL S <=2 R 32 
LAB. 015 
  
  
EURL EC 7.1 Ciprofloxacin, CIP S   R 0.12 
EURL EC 7.2 Ceftazidime, CAZ S 27 R 1 
EURL EC 7.8 Ciprofloxacin, CIP S   R 0.25 
LAB. 016 EURL EC 7.3 Sulfamethoxazole, SMX R >1024 S <=16 
LAB. 019 EURL EC 7.6 Florfenicol, FFN R 32 S 16 
LAB. 022 EURL EC 7.7 Gentamicin, GEN S =16 R 16 
LAB. 023 EURL EC 7.2 Ceftazidime, CAZ S 0.5 R 1 
LAB. 034 EURL EC 7.6 Florfenicol, FFN R 32 S 16 
LAB. 039 EURL EC 7.2 Colistin, COL R 4 S <=1 
LAB. 040 
  
EURL EC 7.2 Ceftazidime, CAZ S 27 R 1 
EURL EC 7.4 Ceftazidime, CAZ S 23 R 2 
LAB. 045 
  
  
  
  
  
  
  
EURL EC 7.1 Ciprofloxacin, CIP S 24.3 R 0.12 
EURL EC 7.2 Ceftazidime, CAZ S 26.3 R 1 
EURL EC 7.4 Ceftazidime, CAZ S 24.0 R 2 
EURL EC 7.5 Ampicillin, AMP R 11.0 S 4 
EURL EC 7.5 Nalidixic acid, NAL R 0 S 4 
EURL EC 7.6 Nalidixic acid, NAL R 12.9 S 4 
EURL EC 7.7 Ceftazidime, CAZ R 10.4 S 0.125 
EURL EC 7.8 Ciprofloxacin, CIP S 22.3 R 0.25 
LAB. 046 
  
  
  
  
EURL EC 7.5 Ampicillin, AMP R 16 S 4 
EURL EC 7.6 Sulfamethoxazole, SMX R >1024 S <=16 
EURL EC 7.6 Trimethoprim, TMP R >32 S <=1 
EURL EC 7.8 Ciprofloxacin, CIP S 0.06 R 0.25 
EURL EC 7.8 Sulfamethoxazole, SMX R >1024 S <=16 
LAB. 056 
  
EURL EC 7.3 Sulfamethoxazole, SMX R >1024 S <=16 
EURL EC 7.5 Sulfamethoxazole, SMX R >1024 S <=16 
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